WO2022005339A1 - Composition pour thérapie et diagnostic à base d'anticorps - Google Patents

Composition pour thérapie et diagnostic à base d'anticorps Download PDF

Info

Publication number
WO2022005339A1
WO2022005339A1 PCT/RU2021/050193 RU2021050193W WO2022005339A1 WO 2022005339 A1 WO2022005339 A1 WO 2022005339A1 RU 2021050193 W RU2021050193 W RU 2021050193W WO 2022005339 A1 WO2022005339 A1 WO 2022005339A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
antibody
addition
antibodies
cells
Prior art date
Application number
PCT/RU2021/050193
Other languages
English (en)
Russian (ru)
Inventor
Петр Иванович НИКИТИН
Original Assignee
Петр Иванович НИКИТИН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Петр Иванович НИКИТИН filed Critical Петр Иванович НИКИТИН
Publication of WO2022005339A1 publication Critical patent/WO2022005339A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens

Definitions

  • the invention relates to the field of biomedicine and nanomedicine, including compositions and methods for the treatment and diagnosis of diseases based on lipid-containing medicinal agents, as well as compositions and methods for improving circulation in the bloodstream, delivery to targets, as well as therapeutic and / or diagnostic efficacy lipid-containing medicinal agents.
  • nanoparticles have a number of advantages over conventional molecular drugs, for example, they have the ability to carry a large amount of the drug, protecting it from degradation, the ability to carry out targeted delivery using even low-affinity receptors due to their multipoint binding of nanoparticles to targets.
  • nanoparticles are used for the diagnosis of diseases, as labels in various biosensors, and also as contrast agents.
  • lipid-containing, liposomal, magnetic for the treatment and diagnosis of diseases such as cancer, stroke, atherosclerosis, infectious diseases (McAteer, M.A., et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide, Nat Med. 13, 1253-8, 2007), etc.
  • lipid-containing nanoparticles (including liposomes) and magnetic nanoparticles are promising agents for the diagnosis and therapy of diseases.
  • they are already approved for intravenous injection in humans for the treatment of a number of diseases.
  • Lipid-containing agents are especially interesting due to their unique properties - biocompatibility, low toxicity of lipids, as well as iron oxides (including those with a low proportion of doping with other elements) , low immunogenicity (in the case of constructing agents from lipids inherent in the patient), the possibility of fusion with the cell membrane and delivery of a tolerable load (payload) directly into the cytoplasm, etc.
  • Such properties allowed lipid-containing agents to occupy a dominant position in the field of nanomedicine, including for gene therapy (for the delivery of genetic information, genome editing systems, etc.).
  • a key problem in this area is the short circulation time of agents in the bloodstream due to the rapid clearance of agents by the immune system. Under conditions of short circulation in the bloodstream, nanoagents do not have time to reach their target in sufficient quantities, which leads to a low efficiency of drug delivery and high systemic toxicity of the drug.
  • RES reticuloendothelial system
  • PEGylation of particles decreases nonspecific interactions of the agent, and also increases the time of its circulation in the bloodstream [Kojima et al., Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics. Nanomedicine. 2011], and the efficiency of agent delivery to the target increases, as well as the diagnostic and / or therapeutic effect produced by it.
  • PEGylated particles it is necessary to distinguish "stele" (the so-called poorly visible by the body) agents, including PEGylated liposomes (for example, the clinically approved drug Kelix for the treatment of cancer), the half-life of which can reach tens of hours.
  • stele the so-called poorly visible by the body
  • PEGylated liposomes for example, the clinically approved drug Kelix for the treatment of cancer
  • this is still significantly less than the circulation time of molecular drugs, for example, monoclonal antibodies. Therefore, prolongation of circulation is required for such agents as well.
  • WO2014039874 A2 The closest method is known (WO2014039874 A2), in which the passive delivery of particles to monocytes (passive - in the sense that it is not mediated by any specific receptors) improves if, in addition to the agent, a fat emulsion (in particular, Intralipid ).
  • Intralipid when introduced into the bloodstream, saturates the cells of the reticuloendothelial system (in this case, mainly Kupffer's cells of the liver) and leads to their blockage (blockade) in terms of their phagocytic activity.
  • the nanoagent introduced after the Intralipid drug circulates in the bloodstream for a longer time and is absorbed by the monocytes / macrophages circulating in the bloodstream much more efficiently than without the administration of the Intralipid drug.
  • the agent is delivered only to actively phagocytic blood cells - monocytes and macrophages, and the delivery is due to the specific activity not of agents, but of target cells, whose task in the body itself is, among other things, to absorb foreign particles. Those.
  • the introduction of a drug that blocks RES significantly changes the composition of the blood of the body, incl. components of the drug - fats, being in the blood in high concentration, can interact with potential targets of the agent.
  • This interaction can have an undesirable effect on the target or interfere with the interaction of the agent with the target, for example, masking them (if the target is cell surface markers), inhibiting phagocytosis of target cells and inhibiting the internalization of the agent into the target cell, etc.
  • This in turn, can significantly reduce the effectiveness of the agent, despite the increase in the time of its circulation in the bloodstream.
  • the required technical result consists in creating a method for increasing the diagnostic and therapeutic efficacy of agents, increasing the efficiency of agent delivery to the body and / or increasing the circulation time of agents (including those based on nano- and microparticles) in the bloodstream of the body (preferably applicable for increasing the effectiveness of the widest possible range of agents) by introducing into the body a minimum amount of potentially foreign and / or toxic objects, if possible, minimally changing the composition of the blood.
  • composition for use in a method of therapy or diagnosis of diseases or conditions of the body, including at least i) an antibody in free molecular form against the patient's blood cells, and i) a lipid-containing nanoagent (or - a drug or therapeutic agent, hereinafter, everything that is said about lipid-containing agents where applicable also applies to liposomal agents and vice versa).
  • composition for improving the efficiency and / or reducing the side effects of the magnetic nanoagent containing at least an antibody against blood cells.
  • compositions for improving the efficacy and / or reducing the side effects of a lipid-containing agent comprising at least an anti-blood cell antibody.
  • compositions for improving the effectiveness and / or reducing the side effects of the liposomal agent containing at least an antibody against blood cells.
  • compositions for improving the efficacy and / or reducing the side effects of a liposomal therapeutic agent comprising at least an antibody against the patient's blood cells.
  • compositions for improving the efficacy and / or reducing side effects of a liposomal therapeutic agent administered in a separate dosage form from said composition contains at least an antibody against the patient's blood cells.
  • a composition for improving the efficacy and / or reducing the side effects of a liposomal therapeutic agent comprising at least an antibody against the patient's blood cells.
  • a collision to improve the effectiveness and / or reduce the side effects of a summer therapy, including the administration of a liposollal therapeutic preparation to a patient is characterized by the fact that the collapse collapse contains, at least, an antibody against the patient's blood cells.
  • a collection for use in therapy or diagnostics comprising, at least, i) an antibody in free llolecular forlle against the patient's blood cells, and ii) a liposollate therapeutic agent.
  • a collection for use in therapy or diagnostics with a HALF liposollal preparation including at least an antibody in the free llolecular forel against the patient's blood cells.
  • the collapse in which the deposited liposollal therapeutic agent is long-circulating in the bloodstream, the vrell half-life of the agent from the bloodstream without administering the collapsed collapse is more than 10 lint, preferably more than 30 lint, preferably more than 1 hour, preferably more than 2 hours, preferably more than 3 hours preferably more than 5 hours, preferably more than 7 hours, preferably more than 10 hours, preferably more than 24 hours.
  • a method for improving the efficacy of a liposollal therapeutic agent comprising: 1) administering a liposollal therapeutic agent, and 2) administering an antibody against blood cells.
  • the method in which the extinguished antibody is administered in a dose effective to improve the efficacy of the extinguished agent.
  • the method in which the extinguished antibody is administered in a dose effective to improve the efficacy of the extinguished agent does not or will show a therapeutic effect.
  • a method for improving the efficacy and / or reducing the side effects of a liposollal therapeutic agent comprising: 1) administering a liposollal therapeutic agent, and 2) administering an abolished collision.
  • the method in which the extinguished antibody is administered in a dose effective to improve the efficacy of the extinguished agent.
  • the method in which the extinguished antibody is administered in a dose effective to improve the efficacy of the extinguished agent does not or will show a therapeutic effect.
  • a collection for use in therapy or diagnostics comprising, at least, i) an antibody in free llolecular forel against the patient's blood cells, and ii) a lipid-containing agent.
  • a phallacetic collation for use in summer therapy or diagnostics comprising, at least, i) an antibody against the patient's blood cells, and ii) a lipid-containing agent, characterized by a lipid-containing agent (hereinafter in the number of illusions in the mean in the number of liposollal therapeutic agent) out of bounds with antibodies.
  • a collection for use in therapy or diagnostics including, at least, i) an antibody against the patient's blood cells, and ii) an unbound lipid-containing agent, characterized by the fact that the antibody is (is) a substance in free llolecular forlle.
  • a collection for use in therapy or diagnostics comprising, at least, i) an antibody against the patient's blood cells, and ii) a lipid-containing agent, different from the fact that the lipid-containing agent is not associated with the antibodies ...
  • the collision in which the antibody in question is polyclonal antibodies.
  • the collision in which the antibodies in question are antibodies isolated from donated blood.
  • the collision in which the dose of the suppressed antibody is selected sufficient for the vrelle circulation in the bloodstream of the suppressed lipid-containing drug to be increased by no more than 30% compared to vrellenella, the circulation in the bloodstream of the suppressed lipid-containing drug without administration of the suppressed antibody ...
  • the collision in which the dose of the suppressed antibodies is selected sufficient so that the vrelle circulation in the bloodstream of the suppressed lipid-containing medicinal agent is increased by no more than 3 times compared to vrellenella circulation in the bloodstream of the suppressed lipid-containing drug without the introduction of the suppressed antibody ...
  • a collision in which the antibodies and the lipid-containing medicinal agent are administered, are administered to the organism in separate dosed forls.
  • the collision which is presented in the form of a single dosed forlla.
  • a collision which is characterized by the fact that the injected antibody and the injected lipid-containing medicinal agent are contained in a single dosed forl or in two different dosed forls.
  • the collision in which the lipid-containing drug agent is administered is liposollalll agentoll.
  • the collision in which the lipid-containing medicinal agent is dropped is a liposollo.
  • composition in which the lipid-containing drug agent is dropped is a PEGylated liposoll.
  • the collision in which the lipid-containing drug agent is administered is liposollalic doxorubicin.
  • the collision in which the lipid-containing drug agent is dropped is PEGylated liposollal doxorubicin.
  • a collision in which the agent to be copied consists of at least one of the following nano or microparticles: lagnitic, fluorescent, protein (including a cross-linked, polylated or aggregated protein), polylated, in t .h. consisting, at least, of one of the following pollers: polystyrene, dextran, polypeptide, glycolic acid polylactide, or block copolymers) or crystalline (gold, silver, semiconducting, or lettallic) nano- or llicparticles.
  • the collision in which the superimposed agent performs the visualizing function due to the product of the detecting signal, incl. at least one of the following: fluorescent, lullinescent, PET signal, MPT-contrast signal, X-ray contrast, lagnitic signal or signal due to plasllon resonance, or signal due to absorption of light or other electromagnet or acoustic waves.
  • a collision in which the agent performs a therapeutic function for example, due to the delivery of cytostatic or cytotoxic compounds, or medicinal compounds, incl. low molecular weight, fertile, radioactive, heliotherapeutic, substances for photodynallic therapy, hyperterllia.
  • the collision is for use in a method of treating cancer.
  • the collision is for use in a method of treating a disease or condition selected from the group consisting of: cancer, atherosclerosis, stroke, heart attack.
  • Kroll in addition, the colposition for use in the method of conducting angiocontrast.
  • composition for use in a method for the treatment of cancer characterized by the fact that first the canceled antibody is administered, followed by the administration of the canceled lipid-containing drug agent.
  • the collapse which additionally contains red blood cells.
  • a collection that additionally contains an erythropoiesis stiller.
  • collapse which additionally contains erythropoietin.
  • a method for diagnosing or treating diseases or conditions of the organism in which i) the collapsed antibody COLLECTION is introduced into the organism, ii) the collapsed lipid-containing drug collision is introduced into the organism.
  • a method characterized by the fact that the agent in question is administered after no more than 10 minutes, preferably not more than 20 minutes, preferably not more than 30 minutes, preferably not more than 45 minutes, preferably not more than 1 hour, preferably not more than 2 hours, preferably not more than 3 hours, preferably not more than 6 hours, preferably not more than 12 hours, after administration of the antibody.
  • the method characterized by the fact that the injection of the canceled antibody into the organism increases the efficiency of the diagnostic or therapeutic action of the canceled agent in comparison with the introduction of the canceled agent without the injection of the canceled antibody.
  • a method characterized by the fact that the administration of a controlled antibody into the organism increases the vrell circulation of the controlled agent in the organism's bloodstream.
  • Kroll in addition, a method, which is characterized by the fact that, along with the introduction of an erythrocyte substance and an erythrocyte agent, erythrocytes are introduced into the organism.
  • the method is characterized by the fact that, along with the introduction of the expelled substance and the expelled agent, the blood of the sally organelle or its counterparts or donor blood or its counterparts are injected into the organelle.
  • a method characterized by the fact that, along with the introduction of the expelled substance and the expelled agent, a collision is introduced into the organism for the stilling of erythropoiesis.
  • Kroll addition a method for the diagnosis or therapy of cancer.
  • Kroll in addition, the method of using collapsed collations for the manufacture of drugs for the treatment of cancer.
  • it is a method of promoting products to the market, which includes, at least, the promotion for scientific research or diagnostics, monitoring or therapy of diseases or conditions of the organism, at least of the collated collision or method.
  • the method of promoting products to the market including, at least, promoting the delivery or improvement of the delivery of nucleic acids (polynucleotides) (gene therapy, delivery of nucleic acids and, in general, all purposes of COLLECTIONS and methods described in this description), at the latest, collated collision or collated method.
  • nucleic acids polynucleotides
  • gene therapy delivery of nucleic acids and, in general, all purposes of COLLECTIONS and methods described in this description
  • a llet characterized by a tell that the advancement is carried out by inserts in a package with a collection collection or its collponentalli (substanceally), containing, at least ller, a collection according to paragraphs. 1-39.
  • it is a llet, characterized by the tell that the promotion is carried out by written or oral communication to the doctor or medical service provider.
  • a business lease that includes, at least, marketing for diagnostics and therapy, or for improving the effectiveness of diagnostics or therapy, or for delivering an agent to an organism, or for increasing the timing of circulation of an agent in the bloodstream of an organism of a given collection or method.
  • a business case involving, at least, marketing to deliver or improve the delivery of nucleic acids (polynucleotides) to an organism or to increase the circulation of an agent in the bloodstream of an organism in a given collection or method.
  • nucleic acids polynucleotides
  • a collision to increase the diagnostic or therapeutic efficacy of a lipid-containing medicinal agent injected into the organism which includes, at least, a collponent, which, when a collision is introduced into the organism, promotes the removal of the reticuloendothelial sistella from the bloodstream at the least, of objects, circulating in the bloodstream, but not being artificially created nano- or llylico-particlesalli or opsoninalli, which binds to the collaponentoll nonspecifically, the canceled excretion of the collapsed objects causes, at least, a partial blockage of the reticuloendothelial systtelle.
  • the collponent is a separate substanceall, which is capable of interfering with an objectalli or objectalli, or, preferably, binding with an objectalli objectalli, or undergoing a chyllic or biochillic, preferably ferventative, reaction in a LLLI.
  • facilitating the elimination of the collponent from the bloodstream means that if a collapse was introduced without such a collponent, the elimination of the collapsed objects from the bloodstream would be more glacial, more preferable much more glacial (several times), or even more preferable there would be no blockage of the RES.
  • a collision for the delivery of a lipid-containing drug into the body which includes, at least, a collponent, which, when introduced into the body, promotes the removal of the reticuloendothelial systella from the bloodstream at the end of the body, objects circulating in the bloodstream, but not which are artificially created nano- or llylico-particlesalli or opsoninalli, which bind nonspecifically to canceled collponentoll, the canceled removal of canceled objects causes, at least, partial blockage of the reticuloendothelial sistella.
  • a collision is characterized by the tell that the object is collapsed or the object is cells.
  • the collapse is characterized by the tell that the object is controlled by the erythrocytes.
  • the collision is characterized by troll cells.
  • a collision characterized by the tell that the object is controlled by the leukocytes.
  • the object is controlled or the object is llolecules.
  • there is a collision which is distinguished by the tell that the collapsed objects are part of the COLLECTION, but are not part of the collateral.
  • a collection characterized by the tell that the object is controlled are the cells or llolecules of the sally organism.
  • the circulation in the free-flow form decreases, for example, if the erythrocyte is absorbed by the llacrophagoll circulating in the bloodstream, then the red blood cell is considered to be removed from the free circulation in the bloodstream.
  • a collision characterized by the tell that the object is destroyed or the object, is the cells that did not leave the organism.
  • a collection which is characterized by the tell that the object is controlled or the object, are cells or llolecules that have entered the organelle of the transfusion of blood or blood donor blood collectors.
  • a collision characterized by the tell that the object is controlled or the object, are cells or llolecules that are part of the COLLECTION, BUT are not collponentoll.
  • a collision that is distinguished by the fact that the collated action of the collapsed collateral with the collapsed object is the linking of the collateral collateral with the collapsed collateral object.
  • the collapsed collateral consists, at least ller, of an antibody, which forms a collapsed specific collplex from the collapsed object, due to direct or indirect recognition and attachment to the collapsed object.
  • a collision characterized by the fact that the accomplished recognition and attachment of the collapsed or indirectly collapsed collponent to the collapsed object causes predominantly phagocytosis of the collapsed objects of the organism's cell, mediated by the Fc receptoroll.
  • collateralized collponent consists, at least ller, of a highly colological type of antibodies of the organism of an antibody (or its variant), incl. autologous, allogeneic, gullanized or chiller antibodies.
  • a collision is characterized by the fact that the collapsed collponent consists, at least ller, of a lonoclonal antibody.
  • a collision characterized by the fact that the collapsed collateral promotes the elimination of collapsed objects, which are the cells that make up the COLLECTION, by recognizing the collapsed cells and promoting their phagocytosis by the reticuloendothelial sistella.
  • a collision is characterized by the fact that the collateralized collponent consists, at least, of several antibodies targeting several different types of cells or llolecules of the organism.
  • a collision which is distinguished by the fact that the collapsed collponent consists, at least of several, at least of lonoclonal, or at least of highly colological types of antibodies of antibodies (or of their collisions and variants), incl. autologous, allogeneic, gullanized or chiller antibodies, against organelle cells or llolecules or their allogeneic analogs.
  • a collision which is characterized by the fact that the collapsed component consists, at least of all, of an antibody combined with another million of substances, including, in the number of molecules, particles, cells or their associations.
  • a collision which is characterized by the fact that the accomplished recognition and attachment of the collapsed or indirectly collapsed collateral to the collapsed object causes phagocytosis of the collapsed objects in other cells of the organism.
  • a collision characterized by the fact that the controlled excretion of the reticuloendothelial sistella of the collapsed objects is caused by their agglutination under the action of the collapsed collponent of the collapse.
  • a collision characterized by the fact that the controlled excretion of the reticuloendothelial sistella of the collapsed objects is caused by their aging under the action of the collapsed collponent of the collapse.
  • a collision characterized by the fact that the controlled excretion of the reticuloendothelial sistella of the collapsed objects is caused by their damage to the cells under the action of the collapsed collateral of the collapse.
  • a collision characterized by the fact that the controlled excretion of the reticuloendothelial sistella of the collapsed objects is caused by their llodification under the action of the collapsed collponent of the collapse.
  • a collision characterized by the fact that the collapsed collateral causes an increase in the phagocytic activity of the cells of the reticuloendothelial sistella of the organism, which remove the collapsed objects from the bloodstream.
  • a collision which is characterized by the fact that the collapsed component is a hyllicell compound, llolecule, particle or cell (including a bacterium, leukocytol, etc.) or a combination of such objects, but does not contain erythrocytes.
  • a collision characterized by the fact that the collapsed component is a hyllicell compound, a molecule, a particle or a cell (including a bacterium, leukocytol, etc.) or a combination of such objects, but does not contain objects obtained by any or lmodification of erythrocytes.
  • collapse the introduction of which into the organism leads to a reduced blockage of the reticuloendothelial sistella, so that the vrell circulation of the reduced lipid-containing drug in the bloodstream increases.
  • a collision the introduction of which into the organism leads to a reduced blockage of the reticuloendothelial sistella, so that the vrelle elimination half-life (or vrelle elimination) of the expelled agent from the circulation in the bloodstream increases no more than the number of cells by 1.2, preferably by 1.5, preferably by 1.75, preferably by 2, more preferably 3, more preferably 5, more preferably 7, more preferably 10, more preferably 15, more preferably 20, and even more preferably 25 times the elimination half-life of the eliminated agent without collision.
  • ETHOLL When ETHOLL is under a cell, for example, it is difficult to lower the cell with or without the amount of water they contain.
  • a collision that is characterized by tellthat in its composition the dose of active colponents, the presence of which causes blockage of the reticuloendothelial sistella does not exceed, at least one of the following doses: 5, 2.5, 1, 0.5, 0.25, 0.1, 0.05 , 0.025, 0.01, 0.005, 0.0025, 0.0015 g / kg body weight.
  • a collision the introduction of which into the organism increases the efficiency of passive or directed delivery of the canceled agent to the target, at least 2 times, more preferably 3, more preferably 5, more preferable 7, and even more preferable 10 times in comparison with cases delivery of the collapsed agent to the client without collision.
  • a collision that is distinguished by the fact that the collateralized collponent consists, at least ller, of llonoclonal or, at least ller, highly colological type of antibodies organelle antibodies, incl. autologous, allogeneic, gullanized, or hiller antibodies (or their variants) capable of specifically recognizing and binding spontaneously or indirectly to cells or llolecules circulating in the bloodstream (naturally circulating or introduced from outside).
  • a collision characterized by the fact that the accomplished recognition and attachment of the suppressed antibodies, either indirectly or indirectly to the cells, causes the phagocytosis of the suppressed cells.
  • a collision characterized by the fact that the controlled recognition and attachment either directly or indirectly to the cells of the collapsed antibodies causes predominantly Fc-mediated phagocytosis of the collapsed cells.
  • a collision the introduction of which into the organism increases the diagnostic or therapeutic efficacy of the extinguished agent by at least 1.3 times as compared to the case of delivery of the expelled agent to the organelle without the introduction of a collision.
  • lagnitic including a cross-linked, polymerized or aggregated protein
  • protein including a cross-linked, polymerized or aggregated protein
  • polylactic including polystyrene, dextran, polypeptide, polylactide glycolic acid or other polylactic and block copolymers, etc.
  • crystalline gold, silver, semiconductor, etc.
  • the collision for which the agent is nano- or microparticles (including particles including nano- or microparticles).
  • a collision characterized by a tell that the agent being controlled is a nano- or microparticle with an average value of one roll of radiosity (i.e., taking into account the variance) exceeding 10 nll, or 19 NLL, or 29 NLL, or 29 NLL, or 49 NLL, or 74 NLL, or 99 NLL, or 199 NLL, or 299 NLL, or 399 NLL, or 499 NLL, or 599 NLL, or 699 NLL, or 799 NLL, or 899 NLL, or 999 NLL, or 1299 NLL, or 1499 NLL, or 1999 NLL, or 2499 NLL, or 2999 NLL.
  • the agent being controlled is a nano- or microparticle with an average value of one roll of radiosity (i.e., taking into account the variance) exceeding 10 nll, or 19 NLL, or 29 NLL, or 29 NLL, or 49 NLL, or 74 NLL, or 99 NLL, or 199 NLL, or 299 NLL, or
  • a collision characterized by a tell that the agent is a nano- or microparticle with an average depletion in one-roll of eradication (i.e., taking into account the variance) not exceeding 10 nll, or 19 NLL, or 29 NLL, or 29 NLL, or 49 NLL, or 74 NLL, or 99 NLL, or 199 NLL, or 299 NLL, or 399 NLL, or 499 NLL, or 599 NLL, or 699 NLL, or 799 NLL, or 899 NLL, or 999 NLL, or 1299 NLL , or 1499 NLL, or 1999 NLL, or 2499 NLL, or 2999 NLL.
  • a collision characterized by the fact that the agent used is used to diagnose or treat diseases or conditions of the organism, including one or more diseases from the following list: cancer, atherosclerosis, stroke, heart attack, incl. including diagnostics of diseases or conditions of the organism using angiocontrast.
  • diseases or conditions of the organism including one or more diseases from the following list: cancer, atherosclerosis, stroke, heart attack, incl. including diagnostics of diseases or conditions of the organism using angiocontrast.
  • a collision which is distinguished by the tell that the agent under control performs a visualizing function due to the product of a detecting signal, incl. at least one of the following list: fluorescent, lullinescent, PET signal, MPT-contrasting signal, ultrasound-contrasting, X-ray contrast, lagnitny signal or signal due to plasllon resonance or another method based on the absorption of agentoll light, electrolagnet, acoustic waves (signals), etc.
  • a collision characterized by the fact that the agent in question performs a therapeutic function, for example, by delivering agents for hyperterllia (lagnitic or gold particles), cytostatic or cytotoxic compounds, or medicinal compounds, incl. low molecular weight, fertile, radioactive, heliotherapeutic, substances for photodynallic therapy.
  • agents for hyperterllia lagnitic or gold particles
  • cytostatic or cytotoxic compounds or medicinal compounds, incl. low molecular weight, fertile, radioactive, heliotherapeutic, substances for photodynallic therapy.
  • a collision to increase the diagnostic or therapeutic effect of INSERTED into the organism of the agent includes, at least, a collponent, which, when introduced into the organism, causes, at least, a partial blockage of the reticuloendothelial sistella of the cell.
  • a collision for the delivery of an agent into the organism which includes, at least, a collponent, which, when introduced into the organism, causes, at least, a partial blockage of the reticuloendothelial sistella of the cell.
  • the number of cells removed from the bloodstream in a certain period of time (10 minutes, 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 15 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days , 5 days, 7 days, or 10 days) significantly increases (by 1.5, 2, 3, 4, 5, 7, 10, 20, 30, 40, 50, 75 or more times) compared to the number of RES cells removed from the bloodstream cells without the introduction of the composition.
  • composition characterized in that said component consists at least of antibodies highly homologous to the specific antibodies of the body against said cells, which provide said blocking of the reticuloendothelial system, incl. an autologous, allogeneic, humanized, or chimeric antibody.
  • composition characterized in that the said component leads to increased excretion of cells circulating in the bloodstream by the reticuloendothelial system, thereby achieving the aforementioned at least partial blocking of the reticuloendothelial system by cells.
  • composition characterized in that said component contains said cells, which block, at least partially, the reticuloendothelial system, due to their rapid removal from the circulation in the bloodstream, sufficient to ensure said blocking of the reticuloendothelial system.
  • composition characterized in that said cells causing said blockage of the reticuloendothelial system are erythrocytes.
  • composition characterized in that said cells causing said blockage of the reticuloendothelial system are platelets.
  • composition characterized in that said cells that cause said blockage of the reticuloendothelial system are leukocytes.
  • composition characterized in that said cells are cells introduced into an organism by transfusion of a donor's or organism's material.
  • composition characterized in that said cells are treated variants of body cells or allogeneic cells.
  • composition characterized in that said treated variants of body cells or allogeneic cells are cells, including those incubated with specific antibodies, that recognize and bind directly or indirectly to said variants of body cells or allogeneic cells.
  • composition characterized in that the said specific antibodies are highly homologous to the specific antibodies of the body, antibodies (or their variants), incl. autologous, allogeneic, humanized or chimeric antibodies.
  • composition characterized in that said specific antibodies are monoclonal antibodies.
  • composition characterized in that said cells are part of said component.
  • composition characterized in that said cells are cells that have not left the body.
  • composition characterized in that the said component specifically interacts with the cells circulating in the bloodstream, and this interaction leads to their excretion from the bloodstream by the reticuloendothelial system, which leads to the aforementioned blockage of the reticuloendothelial system.
  • a collision which is characterized by the fact that the suppressed interaction of the collapsed component with the cells circulating in the bloodstream is the binding of the collateral cells with the collapsed cells.
  • a collision characterized by the fact that the collapsed collponent consists, at least, of an antibody that forms a collapsed specific collplex from the collapsed cell due to direct or indirect recognition and attachment to the collapsed cell.
  • a collision characterized by the fact that the accomplished recognition and attachment of a proliferated or indirectly collapsed collponent to the cells, causes predominantly phagocytosis of the collapsed cells of other cells of the cells of the organism, mediated by the Fc receptoroll.
  • a collision characterized by the fact that the collapsed cells are agglutinated cells, and either are part of the collapsed collateral, or agglutinated under the action of the collapsed collateral.
  • a collision characterized by the fact that the collapsed cells are damaged cells, and either are part of the collapsed collateral or are damaged under the action of the collapsed collateral.
  • the canceled lodified cells are fertilely lodified, incl. with a band of neurallinidase, trypsin, galactose oxidase, etc.
  • a collision is characterized by the fact that the collapsed collateral consists, at least, of several antibodies targeting several different types of organelle cells or their allogeneic variants.
  • collateralized collateral consists, at least of several, of several, at least of, lonoclonal, or at least of high-level, of antibodies of the body of antibodies (or their combinations and variants), incl. autologous, allogeneic, humanized or chimeric antibodies against body cells or their allogeneic variants.
  • composition characterized in that said component is different from an erythrocyte or a modified erythrocyte.
  • composition characterized in that said agent is nano- or microparticles (including particles including nano- or microparticles).
  • composition characterized in that said agent is a nano- or microparticle with a size in one of the dimensions exceeding 10 nm.
  • a composition the introduction of which into the body leads to the said blocking of the reticuloendothelial system so that the half-life (or elimination time) of the said agent from circulation in the bloodstream increases by at least 1.2, preferably 1.5, preferably 1.75, more preferably 2, more preferably 3, more preferably 5, more preferably 7, more preferably 10, more preferably 15, more preferably 20, and even more preferably 25 times the half-life of said agent without administration of the composition.
  • composition characterized in that the dose of active components in its composition, the presence of which causes blockage (or one way or another leads to blockage) of the reticuloendothelial system, does not exceed 5 mg / kg of body weight.
  • composition the introduction of which into the body increases the efficiency of delivery (passive or directed) of the said agent to the target, at least 2 times, more preferably 3, more preferably 5, more preferably 7, and even more preferable 10 times compared to with the case of delivery of the said agent to the target without administration of the composition.
  • a composition the introduction of which into the body increases the diagnostic or therapeutic efficacy of the said agent, at least 1.3 times in comparison with the case of delivery of the agent to the target without administration of the composition.
  • composition characterized in that said agent consists of at least one of the following nano or microparticles: magnetic, fluorescent, protein (including a cross-linked, polymerized or aggregated protein), polymeric (from polystyrene, dextran, polypeptide, polylactide glycolic acid, etc.) or crystalline (gold, silver, semiconductor, etc.) nano- or microparticles.
  • composition characterized in that said agent is used for the diagnosis or therapy of diseases or conditions of the body, including one or more diseases from the following list: cancer, atherosclerosis, stroke, heart attack, incl. including diagnostics of diseases or conditions of the body using angiocontrast.
  • diseases or conditions of the body including one or more diseases from the following list: cancer, atherosclerosis, stroke, heart attack, incl. including diagnostics of diseases or conditions of the body using angiocontrast.
  • composition characterized in that said agent performs a visualizing function by producing a detected signal, incl. at least one of the following: fluorescent, fluorescent, PET, MPT contrast, radiopaque, magnetic, or plasmon resonance
  • composition characterized in that said agent performs a therapeutic function, for example, by delivering cytostatic or cytotoxic compounds or medicinal compounds to targets, incl. low molecular weight, enzymatic, radioactive, chemotherapeutic, substances for photodynamic therapy, hyperthermia.
  • a collision introduced into the organism in order to increase the diagnostic or therapeutic effect of the agent and containing, at least, highly colologic vidyll antibodies of the organism antibodies against erythrocytes or trollbocytes (or their variants), incl. autologous, allogeneic, gullanized, or chiller antibodies.
  • a collision containing, in number, erythrocytes or trollbocytes.
  • a collision introduced into the organism in order to increase the diagnostic or therapeutic effect of the agent or to deliver the agent or to increase the circulation time of the agent in the bloodstream and containing, at least, highly colologic VIDOVYLL antibodies of the organism, antibodies against erythrocytes or trollbocytes (or their variants) , incl. autologous, allogeneic, gullanized, or chiller antibodies.
  • a collision introduced into the organism in order to increase the diagnostic or therapeutic effect of the agent and containing, at least, highly colologic VIDOVYLL antibodies of the organism antibodies against erythrocytes or troll cells (or their variants), incl. autologous, allogeneic, gullanized, or chiller antibodies.
  • a method for diagnosing or treating diseases or conditions of the organism in which: i) one of the above COLLISIONS is introduced into the organism, at least, ii) before or after the introduction of the collapsed collision, or simultaneously with the collapse of the collision, an agent is introduced mediating the diagnostic or therapeutic action.
  • Kroll of the method which is characterized by tell, is that the agent is administered no later than 6 hours and no more than 18 hours after the administration of the copied collection.
  • Kroll of the method characterized by the fact that the agent is injected after no more than 11 hours and no more than 13 hours after the introduction of the collapse.
  • Kroll of the method characterized by tell that the agent to be administered is administered no later than 20 days, preferably 15 days, preferably 10 days, preferably 7 days, preferably 5 days, preferably 4 days, preferably 3 days, preferably 2 days, preferably 1 day, and even more preferably 15 hours after the introduction of the collated collection.
  • Kroll of the method characterized by the fact that the controlled introduction into the organism of the canceled collision increases the effectiveness of the diagnostic or therapeutic action of the canceled agent by increasing the timing of the circulation of the canceled agent in the organism's bloodstream.
  • Kroll is a method characterized by the fact that, along with the introduction of the canceled collapse and the canceled agent, a reducing agent is introduced into the organism, which causes an increase (in comparison with the cases without the administration of the canceled reducing agent) in the level of cells or llolecules, the removal of which from the bloodstream causes the canceled collapse of the canceled collapse.
  • Kroll of the method characterized by the fact that the reducing agent used is the blood of the Sally organelle or its colponentally or donated blood or its colponentally.
  • a collposition for delivery of a lipid-containing drug to the organism and / or increasing the diagnostic or therapeutic efficacy of a lipid-containing drug and including, at least, a collponent or colponents, which i), when introduced into the organism, lead to augmentednoll the elimination of cells or llolecules of the organism from the circulation in the bloodstream, or ii) when introduced into the organism, lead to an increased excretion from the circulation in the bloodstream of cells or llolecules introduced into the organism, or iii) sally are cells, which are rapidly eliminated from the circulation after the introduction of COLLPOSITION into the organism in the bloodstream, in these cases, the increased or rapid elimination of the canceled cells or llolecules from the circulation in the bloodstream leads to an increase in the timing of the circulation of the canceled agent in the bloodstream.
  • a collposition for delivery of a lipid-containing drug to the organism and / or facilitating the delivery of a lipid-containing drug to the organism and / or for increasing the diagnostic or therapeutic efficacy of the agent and including, at least, a collponent or colponents that i) when introduced into the organism lead to enhanced Nolla excretion of cells or llolecules of the organism from the circulation in the bloodstream, or ii) when introduced into the organism lead to enhanced Nolla excretion of cells or llolecules introduced into the body from circulation in the bloodstream, or iii) Sally are cells or llolecules after the introduction of COLLPOSITIONS in the body, they are quickly removed from the circulation in the bloodstream, and in these cases, the increased or rapid removal of the canceled cells or llolecules from the circulation in the bloodstream leads to an increase in the timing of the circulation of the canceled agent in the bloodstream.
  • the method of delivery of a lipid-containing drug into the organism into which: i) inject into the organism, at least one of the above COLLECTIONS, ii) before or after the introduction of the collapsed collection or simultaneously with the introduction of the collapsed collision, the collapsed agent is administered, if it is is not a collponentoll collection.
  • Kroll is a method, which is characterized by the fact that the agent to be suppressed mediates a diagnostic or therapeutic effect.
  • Kroll of the method which is characterized by tell, is that the agent is administered no later than 6 hours and no more than 18 hours after the administration of the copied collection.
  • Kroll of the method which is characterized by the fact that the agent is injected after no more than 4, 7, 13, 30, 50, 70, 100, 125, 150, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 hours after the introduction of the canceled collection.
  • Kroll of the method characterized by the fact that the agent is injected after no more than 11 hours and no more than 13 hours after the introduction of the collapse.
  • Kroll of the method characterized by the fact that, along with the introduction of the canceled collapse and the canceled agent, a reducing agent is introduced into the organism, which causes an increase (in comparison with the cases without the introduction of the canceled reducing agent) the level of cells or llolecules, the enhanced or rapid removal of which from the bloodstream causes the canceled collagen collapsed.
  • the reduced reducing agent is the blood (or its colponentally) of a sally organelle or donor.
  • a collision introduced into the organism in order to increase the circulation of the lipid-containing drug in the bloodstream of the organism containing at least: i) component 1, which, when introduced into the body, leads to an increased elimination from circulation in the bloodstream of erythrocytes or platelets that have entered the bloodstream either naturally or artificially, compared to the rate of their removal in the case without the introduction of the said component, or ii) component 2 , consisting at least of an antibody (or its variants) highly homologous to the specific antibodies of the organism, incl. an autologous, allogeneic, humanized or chimeric antibody capable of forming, directly or indirectly, a specific complex with objects that are naturally in the body or that have entered the body artificially.
  • the mentioned objects can be molecules, particles, cells, as well as their various variants or their combinations, incl. complexes.
  • composition characterized in that said antibody of said component 2 is a gamma immunoglobulin.
  • said objects may be cells.
  • Cells that entered the body naturally mean cells of the body itself, which were naturally created in the body and did not leave the body, while cells that entered the body artificially mean cells that were introduced into the body, including ... cells of the body that were isolated from the body and then injected back into it. The same is true for other objects, such as molecules.
  • composition characterized in that said erythrocytes or platelets that have entered the bloodstream artificially, or said objects that have entered the body artificially, have been introduced into the body by transfusion of material from a donor or body material.
  • said material introduced into the body by transfusion is the blood of a donor or the body itself or its components.
  • composition characterized in that said erythrocytes or platelets that have entered the bloodstream artificially, or said objects that have entered the body artificially, are a component of said composition.
  • composition characterized in that said erythrocytes or platelets that have entered the bloodstream by artificial means are part of said component 1 of the composition.
  • composition characterized in that the said erythrocytes or platelets, which are intensively removed from the circulation in the bloodstream, are treated variants of body cells or allogeneic cells, either being one of the components of the composition, or entering the body artificially.
  • composition characterized in that said treatment of variants of body cells or allogeneic cells includes incubation with specific antibodies that recognize and bind directly or indirectly to said variants of body cells or allogeneic cells.
  • composition characterized in that said specific antibodies are monoclonal antibodies.
  • composition characterized in that said objects are erythrocytes.
  • composition characterized in that said objects are leukocytes.
  • composition characterized in that said objects are platelets.
  • composition characterized in that said objects are albumin.
  • composition characterized in that said objects are immunoglobulins.
  • a collection that is characterized by the tell that the object is killed and the object has entered the bloodstream of the artificial putell are the object that has been introduced into the organism.
  • a collision characterized by the fact that the collapsed collateral 1 or the collapsed collponent 2 leads mainly to the enhanced collapse of the removal of erythrocytes or trolbocytes from the collapsed circulation, which did not leave the organism.
  • a collision characterized by the fact that the collapsed action of the collapsed collateral 1 or the collapsed collponent 2 from the collapsed erythrocytalli or trollbocytalli or objectalli is the binding of the collponent ells with the collapsed or trollbocytalli object.
  • a collision characterized by the fact that the agent being tested is a nano- or microparticle with a single roll of radiation exceeding 10 nill.
  • a collision characterized by the fact that the suppressed increased excretion of erythrocytes or troll cells or objects is caused by their agglutination under the action of the collapsed collateral 1 or collapsed collateral 2 of the collision.
  • collapse characterized by the fact that the collapsed collponent 1 or collponent 2 causes an increase in the phagocytic activity of the organelle cells, which leads to an enhanced collapse of the collapsed erythrocytes or trolbocytes or objects from the circulation.
  • a collapse characterized by the fact that an increase in the time of circulation of the extinguished agent is caused, at least, by a partial blockage of the reticuloendothelial sistella of the organism due to the removal of erythrocytes or trolley cells or objects from the circulation in the bloodstream.
  • collateralized collponent 1 consists, at least of all, of a highly colological type of antibodies of the organism of antibodies (or its variants), incl. an autologous, allogeneic, gullanized, or hillerized antibody capable of specifically recognizing and binding spindle or indirectly to erythrocytal or trollbocytal.
  • a collision characterized by the fact that the collapsed collponent 1 forms a specific collplex with erythrocytal or trollbocytal due to direct or indirect recognition and attachment of erythrocytal or trollbocytall to the collapse.
  • a collision which is distinguished by the fact that the copied antibody of the collapsed collateral 2 forms a collapsed specific collplex with the collapsed object, due to direct or indirect recognition and attachment to the collapsed object.
  • the collapsed collateral 1 or the collapsed collponent 2 consists, at least ller, of several highly collological types of antibodies of the organism of antibodies (or their variants), incl. autologous, allogeneic, gullanized, or chiller antibodies.
  • a collision which is characterized by the fact that the collapsed antibodies of the collapsed collateral 2 are llonoclonal antibodies, or the collapsed collponent 1 consists, at least, of the collapsed collponent antibodies.
  • a collision characterized by the fact that the collapsed antibody of collapsed collateral 2 is combined with other substances, including, in the number of lololecules, particles, cells or their associations, or in which collapsed collponent 1 or collapsed collponent 2 consists, at least , from an antibody combined with another million substances, including, in the number of molecules, particles, cells, or their combinations.
  • the collapsed collateral 1 or the collapsed collponent 2 consists, at least ller, of several highly collological types of antibodies of the organism of antibodies (or their variants), incl. autologous, allogeneic, gullanized or chiller antibodies directed against organelle cells or llolecules or their allogeneic variants.
  • the collapsed collponent 1 or the collapsed collponent 2 consists, at least, of a collplex of llolecules or cells (or their allogeneic variants) isolated from the organelle and associated pryallo or indirectly with NILLI highly gallially vidyll vidyll antitellar or their variants), incl. autologous, allogenic, gullanized, or hillernally antibodies.
  • the collapsed collponent 1 or the collapsed collponent 2 consists, at least, of a collplex of llolecules or cells (or their allogeneic variants) isolated from the organelle and highly-logical types of antibodies of the organism of antibodies (or their variants), .h. autologous, allogeneic, gullanized or chiller antibodies, against data of all llolecules or cells (or their variants).
  • a collection characterized by the telltale of collponentoll 1 or collaponentoll 2 are collapses of cells or llolecules isolated from the organelle or their allogeneic analogs specifically associated with antibodies against erythrocytes or trollbocytes.
  • a collision characterized by the fact that the collapsed collponent 1 or the collapsed collponent 2 consists, at least, of a collplex of a substance (llolecules, cells, particles, etc.) non-covalently connected by a specific biololecular bond with the erythrocyltol ( or their allogenic analogue).
  • a collection that is distinguished by the fact that the collapsed collateral 1 or the collapsed collponent 2 consists, at least ller, of a highly colloquial type of antibodies of the organism of antibodies (or its variants), incl. an autologous, allogeneic, gullanized or hillerized antibody capable of specifically recognizing and binding spindle or indirectly to cells or llolecules circulating in the bloodstream (naturally circulating or artificially introduced).
  • the collision which is characterized by the fact that the antibodies that are capable of specifically recognizing and binding either indirectly or indirectly to the cells or llolecules circulating in the bloodstream, is the llonoclonalnyl antibodies.
  • a collision characterized by the fact that the antibodies (or variants thereof), capable of specifically recognizing and adhering spontaneously or indirectly to cells or llolecules circulating in the bloodstream, are connected to other millions of substances, including, in toll, llolecules, particles, cells or their associations.
  • a collision which is distinguished by the fact that the collapsed collateral 1 or the collapsed collponent 2 consists, at least, of several, at least lonoclonal, or at least highly colological types of antibodies of the organism of antibodies (or their collbations and variants), in t. h. autologous, allogeneic, gullanized or chiller antibodies, against organelle cells or llolecules or their allogeneic analogs.
  • the antibody lays down to be directed against, for example, cellular llarkers of these cells, certain epitopes of cellular llarkers, etc.
  • a collision that is distinguished by the fact that the collapsed collateral 1 or the collapsed collponent 2 consists at least of several, at least lonoclonal, or at least vysokogolologicheskogo VIDOVILL antibodies of organelle antibodies (or their collections and variants). h. autologous, allogeneic, gullanized or chiller antibodies against different cells or llolecules of the organelle or their allogeneic analogs.
  • the collapse which is different, is that the collapsed collponent 1 is different from the erythrocyte or lodified erythrocyte.
  • a collision the introduction of which into the organism leads to an increase in the rate of circulation of the extinguished agent in the bloodstream so that the vrelle elimination half-life (or vrelle elimination) of the agent from the circulation in the bloodstream increases no more than the number of people by 1.2, preferably 1.5, preferably 1.75, more preferable 2, more preferably 3, more preferably 5, more preferably 10, more preferably 12.5, more preferably 15, more preferably 20, and even more preferably 25 times the half-life of the agent without administration
  • a collision the introduction of which into the organism increases the vrelle circulation of the agent, the introduction of which, in turn, is used for the diagnosis or monitoring or therapy of a disease, while an increase in the circulation time of the canceled agent increases the efficiency of the diagnosis or therapy of the disease.
  • a method for increasing the circulation of a lipid-containing drug in the organelle's bloodstream into which: i) is injected into the organelle, at least one of the above COLLEGES, ii) is injected into the expelled organelle.
  • Kroll of the method which differs from the tell, that the dose of the reduced colposition is selected when it is introduced into the body to increase the reduced circulation rate by the required number of times, optillizing the beneficial effect of increasing the circulation rate, and POSSIBLE negative effects (e.g., lowering the concentration of llolecules or blood cells, withdrawal organally RES).
  • Kroll of the method which is characterized by tell, is that the dose of the reduced collapse is selected when it is introduced into the body to increase the reduced circulation rate by the necessary number of times, optimizing the beneficial effect of increasing the circulation time, and POSSIBLE negative effects.
  • Kroll of the method differing tell, that the introduction of the collapsed collision or its variants is repeated many times.
  • Kroll of the method differing tell, that the introduction of the collapsed collision or its variants is repeated many times.
  • a collision is subdivided that is different in composition from the collated one, but it is also a pre-bulletin of the present invention by its own indications.
  • Kroll of the method which is characterized by the fact that, along with the introduction of the canceled agent and the canceled collision, a reducing agent is introduced into the organism, causing an increase in the level of cells or llolecules, which are intensively removed from the circulation in the bloodstream under the action of the canceled collapse, in comparison with Trowells without the introduction of the canceled reducing agent ...
  • Kroll of the method characterized by the fact that, along with the introduction of the canceled agent and the canceled collision, a reducing agent is introduced into the organism, causing an increase in the level erythrocytes or platelets in the blood compared with the level without the administration of the said reducing agent.
  • a method characterized in that said reducing agent is the blood of the organism itself or its components or donor blood or its components.
  • a composition introduced into the body in order to increase the diagnostic or therapeutic effect of the agent introduced into the body, and including at least a component that, when introduced into the body, leads to at least partial blockage of the reticuloendothelial system due to active excretion it from the circulation in the bloodstream of at least one of the following substances: i) cells or molecules of the organism itself, or ii) cells or molecules that have entered the body artificially, but not included in the composition, or iii) cells included in the composition compositions, incl. included in the mentioned component.
  • a composition for increasing the diagnostic or therapeutic effect of a lipid-containing drug agent includes at least a component that, when the composition is administered to the body, promotes the removal of the reticulo-endothelial system from the circulation in the bloodstream, at least of objects that are cells or molecules, if the mentioned molecules are not excreted from the bloodstream mainly as nonspecifically interacting with the aforementioned component of opsonins, and the said removal of the mentioned objects from the circulation in the bloodstream leads to at least partial blockage of the reticuloendothelial system.
  • a composition introduced into the body in order to increase the diagnostic or therapeutic effect of a lipid-containing medicinal agent, and including at least a component that, when introduced into the body, causes active excretion (promotes excretion) from circulation in the bloodstream of body objects or objects introduced into the body regardless of the introduction of the composition, or the cells that make up said component,
  • a composition introduced into the body in order to increase the diagnostic or therapeutic effect of a lipid-containing medicinal agent, and including at least a component that, when introduced into the body, causes active elimination (promotes elimination) from circulation in the bloodstream (cells organism or cells that make up the said composition, or objects introduced into the body, regardless of the introduction of the composition)
  • composition introduced into the body in order to increase the diagnostic or therapeutic effect of a lipid-containing drug agent, and comprising at least a component that, when introduced into the body, causes at least partial blockage of the reticuloendothelial system, at least , one of the following substances: cells or molecules capable of forming a specific complex with the said component.
  • a composition for increasing the diagnostic or therapeutic effect of a lipid-containing drug agent comprising at least a component that, when the composition is introduced into the body, promotes the removal of objects from the circulation in the bloodstream, including cells or molecules, if the said molecules are not excreted mainly as opsonins that interact nonspecifically with the mentioned component, and said excretion leads to at least partial blockage of the reticuloendothelial system
  • compositions introduced into the body in order to increase the diagnostic or therapeutic effect of a lipid-containing drug or to deliver the agent or to increase the circulation time of the agent in the bloodstream, and containing at least highly homologous to the species antibodies of the body antibodies against erythrocytes or thrombocytes (or their options), incl. autologous, allogeneic, humanized or chimeric antibodies.
  • compositions for increasing the circulation time of a lipid-containing medicinal agent in the bloodstream and containing at least highly homologous to the specific antibodies of the body antibodies against erythrocytes or thrombocytes (or their variants), incl. autologous, allogeneic, humanized or chimeric antibodies.
  • a method for increasing the circulation time of lipid-containing medicinal agents in the bloodstream of the body due to the introduction into the said living organism of the said agent along with the composition the introduction of which leads to increased removal of erythrocytes or platelets from the circulation in the bloodstream in comparison with the rate of their removal in the case of without the introduction of the composition, and the composition is different from erythrocytes.
  • a method for increasing the circulation time of a lipid-containing drug in the bloodstream of an organism due to the introduction into said living organism of the said agent along with a composition the introduction of which leads to an increased removal of erythrocytes or platelets from the circulation in the bloodstream in comparison with the rate of their removal in the case of without the introduction of the composition, and the composition is different from modified in any way erythrocytes, incl. destroyed erythrocytes.
  • a method of promoting a product to the market including at least promotion for the diagnosis, monitoring or therapy of diseases or conditions of the body, or for scientific research, at least one of the mentioned compositions or methods.
  • the method characterized in that the promotion is carried out by posting information on the Internet.
  • the method characterized in that the promotion is carried out by publication on the Internet.
  • a method characterized in that the promotion is carried out by publishing on a corporate page on the Internet.
  • a method of promoting products to the market including at least promotion for the diagnosis, monitoring or therapy of diseases or conditions of the body, or for scientific research of an agent, nanoagent, nanoparticle, substance, composition, device, device, method (and etc.) as products that improve their properties (or show improved characteristics / possessing improved or advanced characteristics) when introduced into an organism or as part of one of the completed collections or in rallies of one of the above methods.
  • a business llet that includes, at least, marketing for diagnostics and therapy, or to improve the effectiveness of diagnostics or therapy, or to deliver an agent to the organism, or to increase the timing of circulation of an agent in the organism's bloodstream, at least one of the collapsed collections and ways.
  • a business lease that includes, at least, marketing for the diagnosis, monitoring or therapy of diseases or conditions of the organism, or for the scientific research of an agent, nanoagent, nanoparticle, substance, COLLECTION, device, device, summer medicine (etc. .) as a product that improves its properties (or shows improved characteristics / has improved or advanced characteristics) when introduced into an organism or as part of one of the approved collections or in rallies of one of the approved methods.
  • compositions for improving the magnetic delivery of a therapeutic agent characterized in that said composition contains at least an antibody against the patient's blood cells.
  • a collision for improving the lagnitic delivery of a therapeutic agent characterized by the fact that the collated collation contains, at least, an antibody against the patient's blood cells.
  • a collision for improving the effectiveness and / or reducing the side effects of a therapeutic agent containing lagnitic nanoparticles differs in that the collated collation contains, at least, an antibody against the patient's blood cells.
  • a collision for improving the effectiveness of an agent containing lagnitic nanoparticles characterized by the fact that the collated collation contains, at least, an antibody against the patient's blood cells.
  • a collection for improving the effectiveness of a lagnitic nanoagent which is distinguished by the fact that the collated collection contains, at least, an antibody against the patient's blood cells.
  • a collection for use in therapy or diagnostics comprising, at least, i) an antibody in free llolecular forel against the patient's blood cells, and ii) a therapeutic agent containing at least a lagnitic nanoparticle.
  • the collision in which the agent to be used contains a lagnitic particle from the following group of laterals: iron oxide; iron oxide; doped one of the following elements: nickel, cobalt, zinc, llarganese, lignium; iron oxide, doped with ONE or several other or several elelentally; iron oxide coated with a gold shell.
  • a method for diagnosing or treating diseases or conditions of the organism in which: i) the collapsed collapse is introduced into the organism, the extinguished therapeutic agent is introduced into the organism, a gradient of the lagnitic field is created in the area of the extinguished therapeutic agent.
  • a method of lactic delivery of a therapeutic agent to lagnitism inside the organism, which consists in: i) introducing an antibody against the patient's blood cells into the organism (subject / patient), ii) introducing into organelle of the expelled therapeutic agent, iii) creation of a lagnitic field in the area of the expelled organelle.
  • the way in which the antibodies in question are located is the antibodies) in the free llolecular forlle.
  • a method for diagnosing or treating diseases or conditions of the organism in which: i) the collapsed collapse is introduced into the organism, ii) the extinguished therapeutic agent is introduced into the organism, iii) a lagnitic field is created in the region of the collapsed organism.
  • a method for diagnosing or treating diseases or conditions of the organism in which: i) the extinguished COLLECTION antibody is introduced into the organism, ii) the extinguished therapeutic agent of the collision is introduced into the organism, iii) a lagnitic field is created in the region of the extinguished organism.
  • the way in which the antibodies in question are located is the antibodies) in the free llolecular forlle.
  • composition in which said antibody is an anti-CD47 antibody.
  • the collision further comprises an anti-CD47 antibody.
  • the collection additionally includes a P (ab) -fragment anti-CD47 antibody.
  • the collection additionally includes a P (ab) 2 fragment of an anti-CD47 antibody.
  • the collection additionally includes an anti-CD47 antibody fragment without an Fc fragment.
  • the collision further comprises an anti-CD47 antibody lacking an Fc fragment.
  • the collision is an additional inhibitor of the interaction of the CD47 receptor with the SIRPa ligandol.
  • the collision additionally includes a llolecule that blocks the interaction of CD47 with the SIRPa ligandol.
  • the collection additionally includes blood cells associated with ONLY or several killer compounds from the group: anti-CD47 antibody, P (ab) -fraglent antibodies against CD47, P (ab) 2-fragment of antibodies against CD47, fragment of anti-CD47 antibodies without Fc-fragment, anti-CD47 antibody fragment without Fc-fragment, anti-CD47 antibody lacking Fc-fragment, inhibitor of CD47 receptor interaction with SIRPa ligandol, llolecule, blocking CD47 interaction with SIRPa ligandoll.
  • a method further comprising introducing into the organism (patient) one or more compounds (substances) from the group: anti-CD47 antibody, P (ab) -fragment antibodies against CD47, P (ab) 2 -fragment of anti-CD47 antibodies, fragment of anti-CD47 antibody without Fc-fragment, fragment of anti-CD47 antibody without Fc-fragment, anti-CD47 antibody devoid of Fc-fragment, inhibitor of the interaction of the CD47 receptor with the SIRPa ligandol, llolecule that blocks the interaction of CD47 with the SIRP ligandoll.
  • compounds from the group: anti-CD47 antibody, P (ab) -fragment antibodies against CD47, P (ab) 2 -fragment of anti-CD47 antibodies, fragment of anti-CD47 antibody without Fc-fragment, fragment of anti-CD47 antibody without Fc-fragment, anti-CD47 antibody devoid of Fc-fragment, inhibitor of the interaction of the CD47 receptor with the SIRPa ligandol
  • compositions for improving the efficacy and / or reducing the side effects of a therapeutic agent used to deliver a heterologous polynucleotide containing at least an antibody against the patient's blood cells.
  • a collision to improve the efficiency of delivery of genetic information into an organism with an agent containing, at least, an antibody against the patient's blood cells there is a collision for which the predicted improvement in delivery efficiency is an increase in delivery efficiency to a certain extent.
  • a collision for delivery of a polynucleotide to an organism (or delivery of a polynucleotide encoding a therapeutic gene product to an organism) (or targeted delivery of a gene / polynucleotide) (or delivery of a polynucleotide encoding a therapeutic gene product to an organism), containing, at least, an antibody against the organism's blood cells.
  • a collision for delivery of a polynucleotide to an organism (or delivery of a polynucleotide encoding a therapeutic gene product to an organism) (or targeted delivery of a gene / polynucleotide) (or delivery of a polynucleotide encoding a therapeutic gene product to an organism), containing at least:
  • a collection for the treatment of a disease (or for the treatment of a disease or condition of the organism, caused by a decrease in the disease or an increase in the level of expression, functional activity or lutation of the protein), containing, at least, an antibody against the blood cells of the organism.
  • a collision for the treatment of a disease (or for the treatment of a disease or condition of the organism caused by a decrease in the disease or an increase in the level of expression, functional activity or lutation of the protein), containing at least:
  • a collision in which the agent being dropped is a liposolle containing the dropped heterologous polynucleotide.
  • the collision in which the agent to be deposited includes a lipid.
  • a collision in which the collapsed agent is a collplex that includes the collapsed heterologous polynucleotide and a cationic lipid.
  • a collision in which the collapsed agent is a collplex, which includes the collapsed heterologous polynucleotide and a positively charged poller.
  • the collision in which the agent used includes polyethylenillin.
  • a collection in which the agent to be used contains a dendriller.
  • a collection in which the agent to be copied contains at least one of the following nano or microparticles: lagnitic, fluorescent, protein (including a cross-linked, polymerized or aggregated protein), polylated, incl. consisting, at least, of one of the following pollers: polystyrene, dextran, polypeptide, glycolic acid polylactide, or block copolymers) or crystalline (gold, silver, semiconductor, or letallic) nano- or llic-particles.
  • the collision in which the abolished agent includes a virus includes a virus.
  • a collision in which the agent to be dropped includes a viral vector from the group: adeno-associated virus, adenovirus, lentivirus, herpesvirus, alphavirus.
  • the collision in which the agent being collapsed comprises an adeno-associated virus vector that includes a capsid protein, a gollologous capsid protein sequence selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9 , AAV10, AAV-DJ.
  • a collision in which the agent being dropped, additionally performs a visualizing function due to the product of a detecting signal, incl. at least one of the following: fluorescent, lullinescent, PET signal, MPT-contrast signal, X-ray contrast, lagnitic signal or signal due to plasllon resonance, or signal due to absorption of light or other electromagnet or acoustic waves.
  • a detecting signal incl. at least one of the following: fluorescent, lullinescent, PET signal, MPT-contrast signal, X-ray contrast, lagnitic signal or signal due to plasllon resonance, or signal due to absorption of light or other electromagnet or acoustic waves.
  • the collision in which the agent used includes additional therapeutic substances from the group: cytostatic compounds, cytotoxic compounds, low molecular weight medicinal compounds, ferlents, radioactive compounds, heliotherapeutic compounds, substances for photodynamic therapy, a substance for hypertellia.
  • additional therapeutic substances from the group: cytostatic compounds, cytotoxic compounds, low molecular weight medicinal compounds, ferlents, radioactive compounds, heliotherapeutic compounds, substances for photodynamic therapy, a substance for hypertellia.
  • heterologous polynucleotide is an antisense oligonucleotidol.
  • heterologous polynucleotide is the llal of the interfering RNA.
  • a disease selected from the group: cancer, lung, kidney, liver disease, blood clotting, diabetes, stroke, heart attack, Alzheiller's disease, Parkinson's disease, Huntington's disease, hellophilia, alliotrophilic lateral sclerosis, Gaucher's disease, Pollpe's disease, impaired lledi accumulation, impaired iron accumulation, infectious disease, viral disease, bacterial infection, sepsis, hereditary disease, orphan disease.
  • hormones including growth hormone, luteinizing throat, angiopoietins, angiostatin, erythropoietin, growth factors, trollbopoietin, interleukins, blood factors, histocompatibility receptors.
  • a collision in which a heterologous polynucleotide encodes, at least ller, a genoll editing nuclease is also possible.
  • heterologous polynucleotide encodes, at least, the Cas9 nuclease.
  • the collision in which the antibody in question is polyclonal antibodies.
  • the collision in which the antibodies in question are antibodies isolated from donated blood.
  • a collision in which the dose of the suppressed antibody is chosen sufficient so that the vrelle circulation in the bloodstream of the suppressed therapeutic agent is increased by 30% compared to the vrellenella circulation in the bloodstream of the suppressed therapeutic agent without the introduction of the suppressed antibody.
  • the collision in which the dose of the suppressed antibody is chosen sufficient so that the vrelle circulation in the bloodstream of the suppressed therapeutic agent is increased no more than three times compared to the vrellenella circulation in the bloodstream of the suppressed therapeutic agent without the introduction of the suppressed antibody.
  • a collision in which the dose of the suppressed antibody is chosen sufficient so that the delivery efficiency of the suppressed agent to the target is no less increased by 30% compared to the delivery efficiency of the suppressed therapeutic agent without the administration of the suppressed antibody.
  • the collision in which the dose of the suppressed antibody is selected sufficient to increase the delivery efficiency of the suppressed agent to the target is no less than 3 times compared to the delivery efficiency of the suppressed therapeutic agent without the administration of the suppressed antibody.
  • the collision in which it is presented in the form of a single dosed forlla.
  • collation which is presented in the form of a single dosed forlla, is in the free llolecular forlla.
  • a collision in which the extinguished antibody is administered prior to the administration of the extinguished therapeutic agent is a PEGylated liposollo.
  • the collapse which additionally contains red blood cells.
  • a collection that additionally contains an erythropoiesis stiller In addition, a collection that additionally contains an erythropoiesis stiller.
  • collapse which additionally contains erythropoietin.
  • the collision is for use in a method of treating cancer.
  • the collision is for use in a method of treating a disease or condition selected from the group consisting of: cancer, atherosclerosis, stroke, heart attack.
  • Kroll in addition, the colposition for use in the method of conducting angiocontrast.
  • composition for use in a method for the treatment of cancer characterized by the fact that first the collapsed antibody is administered, followed by the administration of the collapsed lipid-containing drug agent.
  • a method for improving the efficacy and / or reducing the side effects of a therapeutic agent used (intended) for delivery of a heterologous polynucleotide comprising:
  • the method in which the extinguished antibody is administered in a dose effective to improve the efficacy of the extinguished agent.
  • the extinguished antibody in which the extinguished antibody is administered in a dose effective to improve the effectiveness of the extinguished agent, the extinguished antibody alone does not or will show a therapeutic effect.
  • the method characterized by the fact that the agent is administered no more than 18 hours after the administration of the antibody.
  • a method characterized by the fact that the administration of a controlled antibody into the organism increases the vrell circulation of the controlled agent in the organism's bloodstream.
  • erythrocytes are injected into the organism.
  • a method characterized by the fact that, along with the introduction of the antibodies and the antibodies, the organelle is injected with the blood of the organelle or its counterparts or donated blood or its counterparts.
  • Kroll addition a method for the diagnosis or therapy of cancer.
  • the method further includes the step of quantifying the blockage of the reticuloendothelial sistella, which includes administering a controlling agent and irradiating its concentration in the bloodstream after a specified time interval to calculate the blockage characteristic of the reticuloendothelial systella.
  • the method further includes the step of radiating a quantitative characteristic of the blockage of the reticuloendothelial sistella, which includes: a) the step of administering a controlling agent before the controlled administration of the suppressed antibodies and irradiating its concentration in the bloodstream after a certain time interval to calculate the characteristic of blocking the reticulo- endothelial sistella. b) the step of administering the controlling agent after the controlled administration of the suppressed antibodies and eradication of its concentration in the bloodstream after a certain time interval to calculate the characteristic of blocking the reticuloendothelial sistella.
  • a method of delivering a polynucleotide to an organism or a method of delivering a polynucleotide encoding a therapeutic gene product to an organism) to an organism:
  • a method of directed delivery of a gene (polynucleotide) to an organism into which:
  • the agent containing the polynucleotide is introduced into the organism.
  • a method of treating a disease or for treating a disease or condition of the organism caused by a decrease in the disease or an increase in the level of expression, functional activity or lutation of a protein, in which:
  • nanoparticles and “nanoagents” subranges supra-molecular structures, which consist of more than one llolecule.
  • ETHOLL although nanoparticles often denote objects up to 100 nll, in the descriptions of the present invention, objects with large 100 nll people are also reframed - preferably up to 5LLKLL, but in some cases the razller was allowed up to UOnll.
  • Taquill scrambled, under nanoparticles include both nanoparticles and microparticles, microspheres, and the like.
  • particles with the mentioned dimensions are meant, both in all dimensions, and in at least one.
  • Free molecular form a state of a molecule in which it is predominantly not bound (does not form a complex / is not associated) with other molecules or objects (cells / nanoparticles), preferably not covalently bound.
  • said antibody is not associated with said lipid-containing agent.
  • binding in a statistical sense, the standard understanding of "binding" is implied, i.e. the presence of a sufficiently high affinity constant.
  • Therapeutic (or drug) molecules / agents can be understood as substances, substances, molecules, supramolecular agents, nanoparticles, microparticles, nanoagents, microagents, formulations, dosage forms, etc., which are used both for therapy and diagnosis of various diseases or conditions of the body. or a patient, incl. include labels, contrast agents, controlled release components, paramagnetic and magnetic agents, cytotoxic agents, and the like.
  • the said composition is used to improve the effectiveness of agents, nanoparticles and microparticles for carrying out various scientific studies, for example, for biovimaging of tumors, angiocontrast, MRI and CT contrasting of various organs, structures, delivery of various probes, toxins and other known problems using nano- and micro-sized objects.
  • the “therapeutic” function of the agent is interpreted not from the point of view of clinical significance, but also from the point of view of research activities using nanoagents (etc.) as means of nanomedicine.
  • an improvement in the effectiveness of the agent can be the achievement of the same result, but with a lower dose of the agent, higher quantitative indicators (contrast enhancement, detection limit, etc.) are achieved.
  • label or “detectable element” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means.
  • labels include 32P, fluorescent dyes, electron dense reagents, enzymes (for example, as commonly used in ELISA), biotin, digoxigenin, or haptens, and proteins or other entities that can be detected, for example, by incorporating radioactive peptide or antibody tags that specifically react with the target peptide. Any method known in the art for conjugating a labeled antibody can be used, for example, using the methods described in (Hermanson, G. T., Bioconjugate Techniques, Academic press, 2013).
  • the term "pharmaceutical” refers to a composition that is useful in treating a disease or symptom of a disease.
  • treatment refers to any indication of success in the treatment or improvement of a disease, injury, pathology or condition, including any objective or subjective parameters such as decrease; remission; reducing symptoms or slowing down the deterioration of the patient's condition, pathology or patient's condition; slowing down the rate of degeneration; what makes the final stage of the disease less painful; improving the physical or mental well-being of the patient.
  • Treatment or improvement of symptoms can be based on objective or subjective parameters; including results of physical examination, neuropsychiatric examinations, and / or psychiatric evaluation. For example, certain methods presented here can successfully treat cancer by reducing cancer incidence and inducing cancer remission.
  • treatment and its continuation includes the prevention of injury, pathology, condition or disease.
  • the term “therapy” also includes “diagnosis”, and also if a therapeutic agent is used for research purposes (as described above), then the use of a research agent is considered as a “therapy” of a condition or (treatment of a condition). destination.
  • Disease refers to the state of health of a patient or subject to be treated with various drugs, dispersions, or other methods provided herein.
  • contrast agent refers to a composition that, when administered to a subject, improves the detection limit or detection capability of a physical method, technique, or medical imaging device (e.g., X-ray instrument, X-ray, CT, PET, MPT (MRI), ultrasound, and others methods).
  • the contrast agent can enhance the magnitude of signals associated with various structures or fluids within a subject.
  • Patient refers to a living organism suffering from or (possibly) prone to a disease or condition that can be treated by administering a drug, pharmaceutical composition, or agent as defined herein.
  • Non-limiting examples include humans, other mammals, bulls, rats, mice, dogs, monkeys, goats, sheep, cows, deer, and other non-mammalian animals.
  • the patient can be human.
  • controlled release component or “externally activated agent” refers to a compound that, when combined with a composition described herein (including embodiments), releases, under the conditions of use (in a patient), the composition at a controlled rate.
  • Such compounds include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and fine drug carrier substrates, and others. These components are discussed in more detail in US patents 4911920; 5403841; 5212162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
  • the implementation of the "controlled release component” can be a sustained release, sustained release, sustained release, time release, timed release, controlled release, modified release, or sustained release compound.
  • the compound is degraded at the site of administration (eg, subcutaneous, intravenous) or within the digestive tract (eg, stomach, intestines) when the compound and composition are administered orally.
  • the controlled release component is a polymer and may be referred to as a “controlled release polymer”.
  • an agent activated by an external effect can be activated (for example, release a therapeutic agent or bind to a target) as a result of exposure to an external magnetic / electric field, ultrasound, light, an electron beam, as a result of the radioactive decay of any atoms, as a result of interaction with chemical microenvironment, etc.
  • the term "paramagnetic agent” refers to a paramagnetic compound useful in diagnostic imaging techniques (eg, magnetic resonance imaging) as a contrast agent.
  • the paramagnetic agent includes gadolinium, iron oxide, iron platinum, or manganese.
  • cytotoxic agents include, but are not limited to, the following substances: ricin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxyanthracindione Dion, actinomycinoma PE) A, PE40, abrin and glucocorticoid and other chemotherapeutic agents, as well as radioisotopes.
  • Suitable detectable markers include, but are not limited to the following substances, a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator, or an enzyme.
  • lipid is used broadly herein to include triglycerides, liglycerides, monoglycerides, fatty acids, steroids, waxes, and various classes of emulsifiers that are used for emulsion stabilization.
  • each position of a therapeutic agent may contain more than one candidate therapeutic agent.
  • each member of the Markush group should be considered separately, thus containing a different embodiment, and the Markush group should not be read as a whole.
  • all cited references are incorporated herein by reference.
  • MFS-cytoblockade we called a similar method of blocking RES (MFS) by RES-cytoblockade or RES-immunoblokada (MFS-cytoblockade or MFS-immunoblokada).
  • MFS-cytoblockade RES-immunoblokada
  • this method can also be called RES-erythroblockade (MFS-erythroblockade).
  • Blockage (blockade) of the reticuloendothelial system is understood as a condition in which the ability of the reticuloendothelial system to remove any agents from the bloodstream decreases, incl. this can occur as a result of active phagocytosis by RES cells of any objects. In this case, in particular, a decrease in their phagocytic activity and, as a result, an increase in the circulation time of the administered agents in the bloodstream can be observed. In this case, a significant increase in the circulation time of the said agent in the bloodstream is preferable, however, an increase in the circulation time of the agent may not occur if, for example, the agent is able to quickly recognize its target in the body and bind to it.
  • the present invention is fundamentally different from the phenomenon of hitchhiking (RBC-hitchhiking, etc.), in which the agent, by binding to an anti-cell antibody, "clings" to long-circulating blood cells.
  • the essence of the present invention is to prolong the circulation of freely circulating agents in the bloodstream (ie agents not associated with cells), or in free circulation within the blood plasma compartment rather than the blood cell compartment. Circulation in a cell-unbound state provides agents with additional therapeutic options that bound agents do not.
  • This invention improves the delivery of the agent to various targets in the body.
  • the improvement of delivery in some cases is meant in the sense of the effect of the mentioned antibodies on the biodistribution of the agent in organs, tissues, and cells of the body.
  • the induced cytoblockade reduces the accumulation of the agent in the liver, therefore, an increase in the concentration of agents in other tissues is observed, depending on the properties of the agent, the properties of antibodies and their dosage. In this case, it is possible to achieve various changes in biodistribution, which can be used for therapeutic purposes.
  • the hepatoprotective function of the method is achieved.
  • the accumulation of the agent in the bone marrow is increased, which can be used to treat various diseases of the bone marrow.
  • a significant decrease in the accumulation of agents in the liver leads to a significant increase in the accumulation, for example, in tumors. Tk. the size of the liver is often much larger than the volume of other targeted organs; even insignificant changes in the accumulation of agents in the liver lead to a significant increase in accumulation in smaller organs and targets.
  • compositions of this invention can be delivered using liposomes that fuse with the cell membrane or endocytosis, as well as using ligands attached to the liposome, or attached directly to an oligonucleotide that bind to surface membrane receptors. proteins of the cell, which leads to endocytosis.
  • liposomes especially where the liposome surface carries target cell specific ligands, or is otherwise preferentially targeted to a specific organ, specific delivery of the compositions of the present invention to target cells in vivo can be accomplished.
  • compositions include those compositions in which the active ingredient is contained in a therapeutically effective amount, that is, in an amount effective to achieve its intended purpose.
  • the actual amount effective for a particular application will depend, in part, on the condition being treated.
  • such compositions When incorporated into a treatment protocol for a particular disease, such compositions will contain an amount of the active ingredient effective to achieve the desired result, for example, modulating the activity of the target molecule and / or reducing, eliminating or slowing the progression of disease symptoms. Determination of the therapeutically effective amount of a compound in this invention is well within the capabilities and skill of those skilled in the art, especially in light of the detailed description of the present invention.
  • the dosage and frequency (one or more doses) administered to a mammal can vary depending on many factors, for example, whether the mammal is suffering from another disease, the type of concurrent treatment, the mode of administration of the drug, size, age, sex, general health, body weight, body mass index, diet, nature and degree of symptoms of the disease, from complications of the disease or other health problems.
  • Other therapeutic regimens or agents can be used in combination with the methods and compositions described herein (including embodiments). Adjustment and manipulation of established dosages (eg, frequency and duration) is well within the skill of those skilled in the art.
  • Dosages can vary depending on patient requirements and the compound used.
  • the dose administered to the patient should be sufficient to produce a beneficial therapeutic response in the patient over time.
  • the size of the dose will also be determined by the presence, nature and extent of any adverse side effects. Determining the correct dosage for a particular situation is within the skill of the art. Typically, treatment begins with lower doses that are less than the optimal dose of the compound. Thereafter, the dosage is increased in small increments until the optimal effect for the specific conditions is achieved.
  • the dosage and intervals can be adjusted individually to provide levels of compound administered that are effective for the particular clinical condition being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease condition.
  • an effective prophylactic or therapeutic regimen can be planned that does not cause significant toxicity and at the same time is effective for treating the clinical symptoms of a particular patient.
  • This planning should include careful selection of the active compound by considering factors such as the pharmacological activity and toxicity of the compound, relative bioavailability, patient weight, the presence and severity of adverse side effects, and the preferred route of administration of the selected agent.
  • an additional aspect of this embodiment of the invention comprises administering to a patient a suitable pharmacologically active agent (s) in the present invention capable of treating cancer in a formulation of the invention.
  • a suitable pharmacologically active agent comprises an antineoplastic agent (eg, a taxane (paclitaxel, docetaxel, and the like) and the like) or the like.
  • antineoplastic agent eg, a taxane (paclitaxel, docetaxel, and the like) and the like
  • the subject has cancer from the group of primary and secondary liver tumors (e.g., hepatocellular carcinoma, multifocal hepatoma, etc.), solid tumors with local or regional manifestation (e.g., metastatic breast cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer (squamous cell carcinoma), colon cancer, renal cancer, bowel sarcoma, esophageal cancer, melanoma, ependymoma, head and / or neck cancer, and the like) or the like.
  • primary and secondary liver tumors e.g., hepatocellular carcinoma, multifocal hepatoma, etc.
  • solid tumors with local or regional manifestation e.g., metastatic breast cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer (squamous cell carcinoma), colon cancer, renal cancer, bowel sarcoma, esophageal cancer, melanoma, ependymoma, head and / or
  • a lipid-containing drug is used as said agent, which is liposomes, nano-sized lipid droplets, emulsions, solid lipid particles and the like, including those filled with various drugs, for example, molecular drugs - doxorubicin, paclitaxel etc., or nanoparticles - magnetic, gold, etc.
  • an increase in the circulation time of the agent in the bloodstream of the body or blocking of the RES is achieved by introducing antibodies into said living organism, the introduction of which leads to an increased removal of erythrocytes or platelets (including native or intact) from the circulation in the bloodstream of the body as compared to the rate of their removal in the case without the introduction of antibodies.
  • erythrocytes or platelets are meant unchanged cells that have not undergone hemolysis or any physical, chemical or biochemical treatment (such treatment can, for example, be ultrasonic exposure, osmotic lysis, formalin fixation, etc.).
  • the clearance of native cells is mediated by antibodies that interact non-covalently with blood cells.
  • the composition is chosen such that it does not contain erythrocytes, or more generally, modified erythrocytes.
  • said antibody composition interact (bind, recognize due to its antigen-recognition site) with epitopes of erythrocytes or platelets that are located directly in the body, i.e. which are not introduced into the body within the framework of a given effect on the body (i.e., if the body has been previously transfused or transplanted with material that is not associated with the need to modulate the behavior of the agent in the body, then we can talk about such cells and molecules).
  • Modified erythrocytes are understood as substances obtained by any physical, chemical or biochemical treatment of erythrocytes or blood components containing erythrocytes. Such treatment may, for example, be ultrasound, osmotic lysis, formalin fixation, etc. Such modifications can lead to negative toxic effects of these agents.
  • the composition may contain complexes of preselected erythrocytes or other cells or molecules of the body with antibodies (or their variants) complementary to homologous species antibodies of the body, incl. autologous, allogeneic, humanized or chimeric antibodies.
  • a composition containing such complexes will not cause, for example, anemia, and the injected cells or molecules will be excreted by the RES organs, which will lead to blocking of the RES organs.
  • the collection of cells or molecules of the body can be carried out in advance so that the body has time to restore the levels of these substances at the time of administration of the composition.
  • the restoration of the level of these substances can be carried out not only while waiting for the body to restore their content, but also actively contribute to this by introducing reducing agents.
  • a reducing agent for example, can be erythropoietin, which accelerates the maturation of erythrocytes.
  • Another option for administering a reducing agent is donated blood transfusion.
  • the introduction of the reducing agent can be carried out both before and during or after the introduction of the agent and the composition.
  • antibodies non-covalently bind to cells, i. E. in this case, new covalent bonds are not formed, which could lead to undesirable toxic effects of drugs.
  • anti-cell antibody means that the antibody binds or is capable of binding to cells, preferably capable of binding specifically (in the traditional sense of molecular and cellular biology) - i.e. specifically form a complex with cells.
  • the antibody recognizes a specific receptor, receptor epitope, or antigenic determinant of a receptor on a cell.
  • said anti-blood cell antibody is selected to be highly specific for a particular population of blood cells (eg, erythrocytes). In this case, it is preferable that this antibody binds only to this population of blood cells and does not bind to other cells of the body, for example, vascular epithelial cells.
  • allogeneic antibodies against erythrocytes are used, isolated from the repertoire of anti-erythrocyte antibodies of an organism susceptible to autoimmune hemolytic anemia (see Examples with antibody 34-3C) - or from the repertoire of similar autoimmune patients for other blood cells.
  • antibodies are used against antigenic determinants or receptors that are characteristic not only of a certain population of blood cells, but also on other cells of the body, for example, antibodies against the CD47 receptor.
  • a receptor that is sufficiently expressed on blood cells, and also select an appropriate monoclonal or polyclonal antibody or a mixture of different antibodies, so that the administration of antibodies effectively induces phagocytosis of blood cells by the reticuloendothelial system, while minimizing negative effects on other cells expressing this receptor.
  • the specificity of antibodies to blood cells is determined according to standard concepts in the field of molecular and cellular biology. Namely, it is important that the affinity of these antibodies for the selected population is such that the constant of association with a receptor specific for a given cell population is higher than 10 L 6 1 / M, more preferably 10 L 7 1 / M, more preferably 10 L 8 1 / M, more preferably 10 L 9 1 / M, preferably 10 L 10 1 / M, preferably 10 L 11 1 / M.
  • the specificity of an antigenic determinant is also determined according to the standards of cell biology, namely, in the presence of a significantly higher level of expression of this receptor in a given cell population compared to other cell populations.
  • the characterization of the number of antibody molecules bound to an erythrocyte after incubation of cells with a solution of antibodies can be used.
  • the determination of such an indicator can be carried out using flow cytometry or other type of analysis. So, for example, after 1-hour incubation 1 mln. cells in a volume of 10 ⁇ g / ml with a solution of antibodies with a concentration of 10 ⁇ g / ml, this can be 25 molecules / cell, preferably 50 molecules / cell, preferably 100 molecules / cell, preferably 200 molecules / cell, preferably 300 molecules / cell, preferably 500 molecules / cell, more preferably 750 molecules / cell, more preferably 1000 molecules / cell.
  • These numbers and protocol can be changed according to accepted principles in cell biology.
  • the hematocrit, hemolysis, and / or the level of the said cells is assessed to verify the phagocytosis of said cells by the reticuloendothelial system in order to possibly adjust the dose of the administered antibody and / or said lipid-containing agent.
  • the elimination of cells from the bloodstream is facilitated by additional treatment with enzymes.
  • enzymes for example, the treatment of erythrocytes with an enzyme, for example, neuraminidase, trypsin, galactose oxidase, etc. or a combination of enzymes leads to an acceleration of their excretion by the reticulo-endothelial system from the circulation in the bloodstream.
  • the active component or components of the composition can be composed of a combination of different objects, including those that possess the described properties and those that do not.
  • the composition may contain not only, for example, an allogeneic antibody against erythrocytes, but also various auxiliary components such as buffer salts and the like, and in addition, such an antibody may, for example, be conjugated to other molecules, particles, etc. ...
  • the mentioned lipid-containing agent can be a wide variety of substances containing lipids, for example, it can be nano- and microparticles in the usual sense of colloidal chemistry, bacteria or cells (in the preferred embodiment of the invention), various molecules (in the preferred embodiment, macromolecules), macromolecular complexes, etc.
  • Agents can be, inter alia, diagnostic and / or therapeutic (including theranostic) agents or substances that in one way or another mediate diagnostic and / or therapeutic functions. For example, an agent can perform an imaging function from a diagnostic point of view.
  • the agent can be an agent that directly produces a detectable signal (fluorescent, luminescent or radioactive agent), or changes the signal detected from other substances (for example, from water protons for MPT contrast agents).
  • the agent can participate in the production of biochemical signals, which, for example, allow the body to be tested for the presence of a disease and, if necessary, signal it.
  • the agent can perform other functions (including therapeutic ones), for example, for the targeted delivery of drugs, the implementation of a hyperthermic effect on the body (if, for example, it contains magnetic nanoparticles), photodynamic therapy (in one way or another, causing, for example, cytotoxicity due to external radiation), and the like.
  • the said lipid-containing agent may be or may contain one or more substances / elements from the following: therapeutic molecules / agents, labels or other detectable elements, contrast agents, controlled release components, agents activated by external influences, paramagnetic agents, cytotoxic agents ...
  • Example 11 shows how an increased accumulation of Agent in a tumor is recorded non-invasively using an MPQ detector (see Nikitin et al. Nat Nanotechnol, 2014).
  • agents are imaged with magnetic resonance imaging or CT diagnostics.
  • the increased delivery of the agent to the target can be used for therapeutic purposes or simultaneously diagnostic and therapeutic (so-called theranostic) purposes.
  • the requirement of said antibody to be an antibody against red blood cells may be considered broader than the standard understanding of affinity / avidity for red blood cells, but in the ability of said antibody to form, directly or indirectly, a specific complex with an red blood cell.
  • the ability of a substance to form, directly or indirectly, a specific complex with something, for example, with the cells of the body means that either the given substance (for example, an antibody) can directly recognize and bind to any cell or molecule, or recognize and bind to other additional molecules , which in turn (also directly or through other molecules) can bind to these cells of the body.
  • additional molecules can be created by the body itself, or also introduced into the body, including as part of the composition.
  • indirect recognition and binding means that, for example, an antibody may not bind directly to a cell, but rather bind to another molecule that has bound to the cell.
  • a humanized anti-rat immunoglobulin G antibody can recognize and bind to a rat anti-human erythrocyte antibody associated with erythrocytes.
  • circulation in the bloodstream can be understood as circulation in the bloodstream in general (in the "spatial” sense, that is, inside the bloodstream, vessels, capillaries, etc.), and free circulation in the bloodstream (i.e. circulation in free form without association or binding with cells, other agents or objects, for example, if an erythrocyte is absorbed by a macrophage circulating in the bloodstream, then the red blood cell is considered to be removed from free circulation in the bloodstream, although in a spatial sense it is still there in the bed of a blood vessel).
  • withdrawal from circulation is understood to mean withdrawal from free circulation.
  • a reversible short-term retargeting of RES to the body's own cells / molecules is achieved in order to prevent an "attack" on the drug, which is fundamentally different from the known methods, since the dose of the introduced foreign blocking RES agent can be reduced 10-100 times compared to existing methods to achieve a 1000% increase in the half-life of the drug (compared to the circulation time of the drug without the introduction of any additional compositions).
  • dose of the introduced foreign blocking RES agent can be reduced 10-100 times compared to existing methods to achieve a 1000% increase in the half-life of the drug (compared to the circulation time of the drug without the introduction of any additional compositions).
  • a composition contains at least an antibody (or variants thereof) highly homologous to the antibodies of the organism, incl. an autologous, allogeneic, humanized or chimeric antibody capable of forming, directly or indirectly, a specific complex with cells or molecules that are naturally in the body, or that have entered the body artificially.
  • antibodies (or their variants), homologous (mainly highly homologous) to the specific antibodies of the organism are administered to block the organs of RES, incl. autologous, allogeneic, humanized or chimeric antibodies against the patient's blood cells, for example, his erythrocytes, platelets or leukocytes.
  • the organs of RES actively absorb blood cells that have bound with antibodies, after which their phagocytic activity against the agent decreases, in particular, the half-life of the agent from the bloodstream may increase. After the introduction of antibodies, the effect increases for some time, then subsides.
  • the agent is administered after administration of the antibodies, their elimination half-life will increase over time and then decline to the interval that was observed before the administration of the antibodies (see Examples 4-10).
  • antibodies highly homologous to the specific antibodies of the body, incl. autologous, allogeneic, humanized or chimeric antibodies, and not, for example, heterologous anti-lymphocyte serum, for blocking RES, allows you to use only the natural mechanism of removing cells from the blood due to phagocytosis by Fc-receptor-mediated RES cells and does not introduce unnecessary danger (toxicity) due, for example, to the "attack" of phagocytes with anti-lymphocyte serum proteins.
  • the Fc portion of the antibody is identical to the Fc portion of the antibodies of the organism itself.
  • the high homology to the body's antibodies will allow avoiding or minimizing the immune response to the components of the composition, which will allow it to be administered multiple times to achieve the effect.
  • the hematocrit is restored by blood transfusion. This avoids the negative consequences of anemia associated with low hematocrit.
  • One of the embodiments of the invention (when the components of their own blood are removed by the RES cells) is characterized by a low toxicity of the approach, since The absorption of blood components by the RES organs (including erythrocytes) occurs throughout the life of mammals, here this process is only accelerated for a short time.
  • the body processes about 1% of erythrocytes, and to achieve blocking of RES, it is required to remove from blood flow of less than 10% of erythrocytes (in Example 4, the maximum drop in hematocrit was by 10-15%, i.e., from 50% to 45%, and then, the minimum hematocrit was observed on the fourth day), while the blocking effect lasts about 5 -10 days, during which approximately the same number of red blood cells would be processed. Therefore, this method is characterized by low health risks.
  • a natural mechanism is used to remove cells from the bloodstream by RES cells.
  • the antibody non-covalently binds to the cell and signals to the RES cells that this complex must be removed from the bloodstream.
  • An important advantage of the method is that there is no chemical modification of blood molecules / cells, no new covalent bonds are formed, or new chemical compounds, etc., which could cause any toxic effects.
  • an antibody (and / or dose of antibody) is selected that does not or leads to little activation of the complement system, preferentially promoting Fc receptor mediated phagocytosis by RES cells.
  • the composition does not cause agglutination of blood cells.
  • the dose of the agent administered can be varied over wide ranges without fear of vascular embolization.
  • the components of the composition conversely, cause agglutination of blood cells.
  • the choice of the dose of the composition is required to prevent thrombus formation, which leads to vascular embolism.
  • the dose of the injected antibodies is selected to increase the effect of blocking RES or to increase the circulation time of the agent in the bloodstream by the required number of times, optimizing the beneficial effect of increasing the circulation time, and the possible negative effects of lowering the concentration of blood molecules / cells. excreted by the RES cells.
  • This approach can also be used to block phagocytic RES cells in other natural fluids, as well as in body tissues.
  • appropriate agents that cause the phagocytic cells of the RES to actively absorb the cells and / or molecules of the body or other objects their ability to phagocytose the agent decreases, which leads to an increase in the target efficiency of the agent.
  • This invention can be used for diagnostic and / or therapeutic purposes. Including for the purpose of improving the targeted delivery of various lipid-containing agents to various targets in the body.
  • targets can be very diverse, for example, it can be specific cells, tissues, areas of the body (including malignant neoplasms and foci of inflammation).
  • the application of the present invention can be, for example, as follows.
  • An antibody that blocks RES for example, humanized antibodies against erythrocytes
  • lipid-containing agents containing toxic molecules for example, the anticancer drug doxorubicin or cisplatin
  • the agents either through the enhanced permeability and retention effect or through specific anti-cancer antibodies, accumulate in the tumor, where doxorubicin or cisplatin is desorbed and causes the death of tumor cells (as shown in Examples 14-15).
  • a monoclonal antibody is used, preferably against erythrocytes or platelets, even more preferably associated with allogeneic erythrocytes or platelets, preferably with erythrocytes or platelets of the body or allogeneic variants thereof.
  • the monoclonal antibody is selected according to the type and isotype so as to achieve controlled removal of cells from the circulation, predominantly by a certain mechanism, for example, by phagocytosis of cells to which the antibodies have bound, by an Fc-receptor-mediated mechanism (to block, for example, the body's Kupffer cells), agglutination of erythrocytes to filter aggregates by the spleen, due to complement-mediated hemolysis of cells to load the kidneys, etc.
  • a combination of different antibodies is used to influence both the biodistribution of excreted cells or other objects that block RES cells, and the biodistribution of the agent throughout the tissues of the body.
  • the drug will preferentially accumulate in the target (eg, tumor) as well as spleen, lungs, and the like.
  • the use of monoclonal antibodies makes it possible to create a composition with an accurate and well reproducible composition, which is useful for quality control and minimizing the harmful effects of such a composition.
  • polyclonal antibodies are used.
  • xenogenic or xenogenic mixed with allogeneic see Example 13
  • allogenic, isolated from donated blood for example, anti-rhesus RhO (D) antibodies.
  • a humanized or chimeric antibody is used, preferably against erythrocytes or platelets, even more preferably associated with allogeneic erythrocytes or platelets, preferably with erythrocytes or platelets of the body or allogeneic variants thereof.
  • a monoclonal antibody for example, murine or rat
  • a monoclonal antibody against, for example, human erythrocytes, and its subsequent humanization
  • a monoclonal antibody for example, murine or rat
  • a monoclonal antibody for example, murine or rat
  • human erythrocytes and its subsequent humanization
  • antibodies against the CD47 receptor are used as antibodies against erythrocytes.
  • This cell surface marker is a glycoprotein that plays an important role in cell-cell communication.
  • the function of this receptor on red blood cells is to prevent the capture of normal red blood cells by macrophages and other phagocytic cells involved in erythrophagocytosis.
  • Receptor ligand - SIRPA SIRPa, CD172a.
  • an anti-CD47 antibody is used to block the interaction of the receptor with the natural ligand of SIRPa.
  • this antibody leads to the elimination of erythrocytes by the reticuloendothelial system, which leads to its temporary blockage. This, in turn, leads to an increase in the circulation time of various nano- and micro-agents in the bloodstream, which are administered simultaneously or after the administration of these antibodies.
  • These antibodies have a twofold effect. First, these antibodies mediate antibody-dependent phagocytosis of erythrocytes. Secondly, these antibodies screen the CD47 receptor, which signal to macrophages about the "normality" of a given erythrocyte. This allows you to enhance erythrophagocytosis, "deceiving" the recognition system between erythrocytes and macrophages.
  • the CD47 receptor when the CD47 receptor is blocked / shielded, it is no longer able to perform its function of inhibiting erythrocyte phagocytosis by the macrophage.
  • Such a violation of the natural signaling pathway between the erythrocyte and macrophages makes it possible to enhance erythrophagocytosis, due to which the blockage of the reticuloendothelial system is realized.
  • not a full-length antibody is used, but its antigen-binding fragment (Fab, Fab2 or the like), or other inhibitors of the CD47-SIRPa interaction, for example, peptides.
  • composition comprising an anti-CD47 antibody has an additional anti-tumor effect by shielding the CD47 receptor on cancer cells, which prevent phagocytosis by cells of the immune system.
  • antibodies against blood cells are used, which have both the functions of prolonging the circulation of nanoagents introduced into the bloodstream and other functions and activities from the viewpoint of combating target diseases.
  • the composition further comprises a component that results in enhanced clearance of body molecules, preferably macromolecules or macromolecular complexes, from circulation.
  • body molecules preferably macromolecules or macromolecular complexes
  • This is important, including for the comprehensive blocking of cells capable of removing agents from the circulation in the bloodstream, mainly for blocking all types of such cells.
  • This makes it possible to significantly reduce the dose of the agent that must be administered in order to deliver a certain amount of it to the target and to increase the specificity of delivery, i.e. deliver as much of the administered dose of the agent to the target as possible.
  • an antibody or a mixture of antibodies is used simultaneously against several types of blood cells - erythrocytes, platelets and / or leukocytes (including those associated with erythrocytes, leukocytes and / or platelets), more preferably together with components that promote enhanced excretion various molecules (mainly macromolecules or macromolecular complexes) from the body.
  • erythrocytes erythrocytes
  • platelets and / or leukocytes including those associated with erythrocytes, leukocytes and / or platelets
  • components that promote enhanced excretion various molecules mainly macromolecules or macromolecular complexes
  • IVH Intravascular hemolysis
  • anti-RBC antibodies are obtained from a murine model of autoimmune hemolytic anemia (AIHA).
  • AIHA autoimmune hemolytic anemia
  • mice generally require more antibodies for RES cytoblockade, or ii) polyclonal anti-RhD is more effective than 34-3C or TER-119, for example, due to different levels of antigen expression. In both cases, there is some possibility that anti-RhD itself will be effective in improving nanoparticle circulation even at already approved doses of 50-75 mcg / kg.
  • anti-RhD doses have been approved for the treatment of ITP based on the following considerations: 1) there are several safe alternatives such as IVIG; 2) ITP itself is not a life-threatening disease; 3) treatment must be safe for repeated injections (once a month) over a long period of time. Therefore, in some embodiments of the invention, the use of the proposed cytoblockade in combination with nanomedicine would be the treatment of life-threatening conditions (such as cancer) that have different thresholds of efficacy / toxicity. Therefore, with careful control of the risk of intravascular hemolysis, the dose of anti-RhD or anti-RBC clones obtained from AIHA can be significantly increased with an overall increase in the effectiveness of treatment of the disease.
  • administration of said anti-blood cell antibody is used to increase magnetic delivery of a magnetic agent to a target.
  • a specially generated magnetic field is used to hold or direct an agent with increased magnetic susceptibility (magnetic nanoagent, superparamagnetic, ferro- and ferri-magnetic agent) to its target.
  • the agent can contain magnetic nanoparticles, superparamagnetic nanoparticles, ferromagnetic particles, and the like.
  • the external field can be both variable and constant.
  • the increase in the circulation time of the agent in the blood achieved by the introduction of the above antibodies (as described above), leads to a greater accumulation of the agent in the focusing area of the magnetic field.
  • the mentioned focusing of the magnetic field means the formation of such a magnetic field, the strength of which in the target area, or the magnitude of the field gradient in the target area, or the product of these values is greater than in any other parts of the body.
  • an alternating magnetic field is used to actively direct the circulating magnetic agents into the target area.
  • a magnetic field is used as a means of long-term retention of magnetic agents in the target area. It is known that many nanoagents (including lipid-containing drugs), spreading well by the bloodstream in the vessels of the body, quickly enter the target, for example, a tumor. And then, within a fairly short time (minutes, tens of minutes, hours), their concentration quickly decreases, which reduces the therapeutic effect. In this case, in one embodiment of the invention, the magnetic field makes it possible to retain such agents in the target area for much longer, and therefore to implement the desorption of the drug (for example, cytotoxic drugs) to affect the target, for example, to kill tumor cells.
  • the drug for example, cytotoxic drugs
  • Examples 14-15 demonstrate an increase in the effectiveness of antitumor magnetic agents when they are magnetically delivered using said antibodies.
  • One of the ways to generate a magnetic field is to place a permanent magnet, preferably neodymium, near (in the area) of the target.
  • a permanent magnet preferably neodymium
  • electromagnets which are also located near the target.
  • methods of magnetic delivery using gradient coils of an MRI tomograph, as well as other more complex systems consisting of several permanent magnets or electromagnets When forming a focusing system for magnetically controlled delivery, try to achieve the distribution of the force field acting on the magnetic inoagents, which ensures maximum efficient accumulation in the target.
  • the essence of the present invention in one embodiment is to reduce the rate of elimination of magnetic nanoagents from the bloodstream by the immune system.
  • This allows the invention to be used in conjunction with virtually any magnetic focusing (delivery) system that allows an increase in the accumulation of magnetic particles in the target area with traditional systemic delivery of the agent (i.e., without the use of said antibodies).
  • compositions and methods of in vivo transfection according to this invention will significantly advance in the creation of drugs for gene therapy, namely, the treatment of diseases by delivering genetic material directly to certain cells of a patient, in order, for example, to increase the expression of specific genes or reduce the production of a desired protein.
  • the limiting factor of such therapy is direct delivery of nucleic acids to the target cells, the selection of a reliable and efficient viral or non-viral delivery vector is of particular importance.
  • the well-established, traditionally used viral vectors based on adenoviruses, lentiviruses and adeno-associated viruses however, have a number of serious disadvantages, such as immunogenicity and carcinogenicity. Non-viral vectors are safer.
  • polyplexes based on cationic or neutral biodegradable polymers include polyplexes based on cationic or neutral biodegradable polymers, lipoplexes (cationic liposomes, niosomes), complexes of DNA with dendrimers or peptides, as well as combinations of all of the above vectors with other nanoparticles, for example, magnetic, gold, etc.
  • non-viral and viral transgene delivery methods can be combined by encapsulating or complexing viral particles with liposomes, nanoparticles, lipid nanoparticles, polymers, microparticles, microcapsules, micelles, extracellular vesicles, etc.
  • lipid vectors are one of the most commonly used carriers of nucleic acids (NK) for transfection for gene therapy.
  • liposomes are used that bind NKs on the surface or encapsulate them in the internal cavity, formed with cationic lipids (eg DOTMA, DOSPA, DOTAP and DMRIE) used as precursors.
  • Cationic lipids in liposomes are diluted with neutral lipids (eg DOPE) to increase the stability and transfection activity of liposomal vectors.
  • DOPE neutral lipids
  • cationic liposomes are formed using cationic cholesterol derivatives.
  • cationic liposomes are formed through the use of lipidoids.
  • NK delivery is carried out using formally neutral liposomes constructed from zwitterionic lipids.
  • Liposomes (phospholipid vesicles) used for gene therapy (lipofection) compatible with this invention may vary in size, lipid composition, charge, dispersion, method of preparation, membrane fluidity, fusogenicity (tendency to fusion with membranes), phospholipidic capacity components for micelle formation and complexation with DNA.
  • the vesicle charge is determined by the presence of polyions or cationic lipids; membrane fluidity negatively correlates with the amount of cholesterol and depends on the degree of "unsaturated TM" and the length of the fatty acid residues of phospholipids.
  • the efficiency of complexation with DNA is enhanced by the use of cone lipids (e.g. dioleyltrimethylammonium (DOTMA)) which have a high spontaneous micelle capacity.
  • cone lipids e.g. dioleyltrimethylammonium (DOTMA)
  • DOTMA dioleyltrimethylammonium
  • substituted tertiary amines such as DOTMA and DOTPA are used as cationic lipids.
  • cationic lipids positively charged lipids with an ether bond in the glycerol part with different ratios of hydrophobic and hydrophilic parts in the molecule, as well as different distances between them, are used, which provides a wide variety of structures of DNA-liposome complexes.
  • dioleylphosphatidylcholine ( DOPC) and dioleyl phosphatidylethanolamine (DOPE) DOPC
  • DOPE dioleyl phosphatidylethanolamine
  • liposome fusogenicity is reduced by the use of dioleyl phosphatidylethanolamine as phospholipid components of liposomes, which causes increased hydration of lysosomes.
  • Absorption DNA-liposomal complexes are prepared on the basis of cationic liposomes. In one embodiment, the DNA-liposomal complexes are prepared from neutral (zwitterionic) liposomes.
  • native plasmid DNA is enclosed in a phospholipid bilayer and protected from the action of DNases, topoisomerase 1 and fluorescent dyes (ethidium bromide and DAPI), which does not affect its ability to internalize and interact with other membranes.
  • solid lipid nanoparticles [47, 48] with a diameter of about 100 nm, which are aggregates of low molecular weight lipids (fatty acids, cholesterol and their derivatives) suspended in the presence of a surfactant (for example Tween-80, Pluronic).
  • a surfactant for example Tween-80, Pluronic.
  • Such lipid nanoparticles bind NC on the surface through electrostatic interactions.
  • dendrimers are used as gene therapy vectors, which are highly symmetric branched macromolecules with low polydispersity.
  • the agents comprise polycations such as L-polylysine (3000-10,000 Da), polyethyleneimine (5 kDa-100 kDa), as well as complexes of polyethyleneimine (hexamer) with mono-, di- and tricholesterol derivatives, lipospermine (cationic polypeptide sperm with hydrophobic groups).
  • Lipospermin has a high affinity for DNA, while forming non-micellar hydrophobic structures similar to liposomes.
  • the agents can also contain cationic polypeptides that are metabolically active and can block ion channels and inhibit the permeability of mitochondrial membranes to calcium and phosphate ions.
  • the agent may include poly- (alkylacrylic acid) polymers, including non-cytotoxic polyacrylic acid (PAA), which are considered endosomolytic polymers and therefore increase gene expression as well as reduce toxicity in vivo.
  • poly- (alkylacrylic acid) polymers including non-cytotoxic polyacrylic acid (PAA), which are considered endosomolytic polymers and therefore increase gene expression as well as reduce toxicity in vivo.
  • PAA non-cytotoxic polyacrylic acid
  • PLGA-PEI nanoparticles are used as a non-viral vector for the delivery of genetic material, which are capable of self-assembly of DNA and provide higher stability, ease of manipulation and an economical option than cationic liposomes.
  • surface modification of composite PLGA-PEI / DNA nanoparticles by treatment with polyethylene glycol (PEGylation) reduces their cytotoxicity, prolongs their in vivo existence and expression, for example, of plasmid DNA.
  • polyesters poly-b-amino ester, PBAE are used to protect NA from enimatic degradation.
  • gold nanoparticles, carbon nanotubes, quantum dots, silicon nanoparticles are used as a vector for delivery of DNA and RNA.
  • an extended gene-encoding dsDNA, mRNA, non-coding RNAs that regulate the expression of target genes (siRNA, microRNA) were used as the transported material.
  • nucleic acids are delivered from the group: plasmid DNA (pRNA), also small interfering RNA (siRNA), short hairpin RNA (shRNA) and antisense oligonucleotides.
  • viral vectors for the delivery of genetic material were obtained from native viral particles by replacing the virus's own genes with genetically engineered constructs. Protein components of the capsid protect NK from degradation in lysosomes and facilitate the delivery of genetic material to the nucleus.
  • adenoviral vectors were used, which are non-enveloped viral particles with a diameter of 80-100 nm containing double-stranded DNA (dsDNA); adeno-associated vectors (AAV), which usually have a small, non-enveloped virion with a diameter of about 20 nm and a genome of 4.7 thousand bases (thus), represented by single-stranded DNA (ssDNA); gammaretroviruses (mouse leukemia virus) and lentiviruses (HIV-1) (however, the low efficiency of transduction of nondividing cells with gamma retroviral vectors limits their use by transferring genes into hematopoietic cells); lentiviral vectors, which are a protein capsid with a diameter of 80-100 nm, packed in a lipid envelope; herpesvirus vectors, which have great potential for use in the clinic, obtained on the basis of herpes simplex virus type 1 (HSV-1); alphavirus vectors
  • targeting molecules eg, cell receptor ligand peptides
  • viral vectors have been modified by mixing fragments of different viruses or introducing peptide inserts so that the genome of the virus is altered to form chimeric or mosaic capsids.
  • viral vectors are rendered properties uncharacteristic of viruses (eg, the presence of reporter groups) by incorporating synthetic polymers or inorganic nanoparticles into viral particles.
  • the agent is or contains a viral vector.
  • viral vector has a common meaning in the art and refers to a vector derived from various serotypes of gammaretroviruses, lentiviruses, adeno- and adeno-associated viruses, herpes simplex viruses, rhinoviruses, etc., capable of infecting humans, monkeys or others. mammalian species, as well as those obtained from wild-type viruses or by various manipulations with their genes, including rearrangements, insertions, mutations, etc.
  • Such vectors can have one or more wild-type genes, as well as completely or partially deleted sequences, provided that functional flanking regions are preserved, which are responsible for the preservation, replication and correct packaging of the virion.
  • Expression vectors expression cassettes
  • Expression vectors are constructed using known methods to ensure functionality and integrity of its elements, including a transcription initiation region, a nucleic acid molecule of a given sequence, and a terminal region. The composition of these elements is selected in such a way as to ensure their functionality in mammalian cells. Any viral strains or serotypes can be used as a "viral vector" in the present invention.
  • the genome or particle of an rAAV vector (with capsids VP1, VP2 and / or VP3) can include any serotype, for example, AAV-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -1 1, -12, -rh74, -rhlO, or AAV-2i8, where vectors may be based on the same strain or serotype (or subgroup and variant) or be different from each other.
  • An immune response such as the humoral immunity of the host organism, can develop against virtually any vector and component of the delivery system, including viruses, transport proteins, polymer structures, nanoparticles, etc., as well as the polynucleotides themselves or proteins or peptides encoded by this polynucleotide. This can potentially lead to partial or complete inhibition of vector functions and / or disrupt the processes of cell transduction, expression or functions of both the heterologous polynucleotide itself and the functions or activity of the encoded proteins or peptides.
  • the heterologous polynucleotide used for delivery encodes a protein that can be selected from the following group: insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH), growth hormone release factor (GRF), follicle stimulating hormone (FSH) , luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiopoietins, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF) (basic growth factor) bFGF), acidic fibroblast growth factor (aFGF), acidic a-glucosidase (GAA), epidermal growth factor (EGF), transforming growth factor a (TGFa), platelet growth factor (PDGF), insulin growth factors I and II (IGF- I and IGF-II)), TGF, activins, inhibitors, inhibitors, inhibitors, inhibitor
  • the expected effect can be obtained without the specific administration of drugs that suppress the immune response (immunosuppressants).
  • at least one immunosuppressive agent may be added prior to, concurrently with, or after administration of the vector to the subject.
  • an anti-inflammatory agent can be used as such an immunosuppressive agent.
  • compositions and vectors of this invention can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, phosphate-saline solution, dextrose solution, or water, as long as the therapeutic and pharmacological properties of the composition are preserved.
  • the composition can be administered to a subject alone or in combination with other agents that affect dose size, frequency of administration, and / or therapeutic efficacy of the drug.
  • the introduction of the drug can be carried out systemically, regionally, locally or in any other way, for example, by injection or infusion.
  • Delivery of pharmaceutical compositions in vivo, as a rule, can be carried out both by injection using a conventional syringe and other known methods of drug administration.
  • the compositions can be delivered subcutaneously, epidermally, intradermally, intrathecally, intrabitally, intramucosally, intraperitoneally, intravenously, intrapleurally, intraarterially, orally, intrahepatically, through the portal vein, or intramuscularly.
  • compositions and methods in some embodiments of the invention, can reduce the side effects of agent administration.
  • the side effects of the agent are reduced compared to the administration of agents based on magnetic particles, polyethyleneimine and polynucleotides (from Examples 27-29) in 12 hours after the administration of antibodies, the toxicity of these complexes decreases, namely, significantly reduces the lethality ... So, for example, if, 12 hours after the administration of antibodies, a dose of such an agent is administered twice as high as the LD50 for the control experiment without the administration of antibodies, then all animals in the experiment survive.
  • this allows for significantly higher doses of agents to be administered and to achieve significantly greater delivery of the payload of an agent, for example, a polynucleotide (which in turn leads to a significant increase in the expression of a protein or targeted nucleic acid).
  • an agent for example, a polynucleotide
  • a therapeutic agent in particular, said agent for delivering a polynucleotide
  • said antibody for example, in which said antibody is an antibody against erythrocytes
  • this interleukin has protective properties, prevents excessive activation of inflammation, inhibits the cytotoxic activity of NK cells, etc.
  • an additional level of control over the specificity of the therapeutic effect is achieved.
  • the mentioned antibody with effector functions is selected, which is personalized for the patient (including with a selected dose) or applied to a certain group of patients based on the analysis of their genome or determination of the probability of higher expression or susceptibility to IL-10, or with by control measurement of the level of IL-10 in response to the introduction of a small dose of this antibody to the patient before therapy (see [Robak, Blood, 2012]).
  • the introduction of such antibodies allows to reduce the systemic activity of the drug delivered by the agent (for example, the expression of a protein or nucleic acid from a therapeutic polynucleotide agent), especially in macrophages and other cells of the reticuloendothelial system, but to increase or maintain such activity in target cells.
  • the agent for example, the expression of a protein or nucleic acid from a therapeutic polynucleotide agent
  • the introduction of such antibodies allows to reduce the systemic activity of the drug delivered by the agent (for example, the expression of a protein or nucleic acid from a therapeutic polynucleotide agent), especially in macrophages and other cells of the reticuloendothelial system, but to increase or maintain such activity in target cells.
  • the state of the mononuclear phagocytic system and the degree of its blockage are additionally controlled depending on the administration of antibodies using an additional controlling agent.
  • Administration of a controlling agent allows the rate of elimination of nanoagents from the bloodstream of organisms to be measured as a control measure.
  • a fluorescently labeled liposomal monitoring agent is administered to the body, and then measurements of the level of this monitoring agent in the bloodstream are carried out either non-invasively by measuring the fluorescent signal from the monitoring agent, or invasively using blood sampling at certain time intervals. intervals and also measurements of the fluorescent signal in the given samples.
  • the characteristic of the circulation time or other quantitative parameter determining the rate of excretion of the controlling agent from the bloodstream is calculated based on the obtained data. It can be a characteristic of half-life, the area under the circulation curve, and based on measurements over a relatively short period of time, for example 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours or more.
  • a quantitative characteristic can be a percentage of the administered dose over a certain period of time.
  • several such reference points can be used to refine a given quantitative characteristic.
  • such a quantitative time characteristic is measured before the administration of the said antibodies, as well as after the administration.
  • comparing these values determine the degree of blocking of the mononuclear phagocytic system in quantitative terms. This procedure allows you to evaluate and measure the effectiveness of these antibodies in a particular patient, as well as to evaluate the effectiveness of dosage of these antibodies to induce cytolacade. This allows, if necessary, to adjust either the dose or the specificity of antibodies (that is, choose the optimal antibody for therapy or use an antibody of a different specificity) individually (personalized) for a particular patient.
  • This procedure also avoids the negative effects of administering said polynucleotide delivery agent if the patient is unresponsive to said antibodies.
  • an important characteristic of the controlling agent is low toxicity and the ability to produce a strong and pronounced detectable signal for its highly sensitive registration and reduction of the administered dose.
  • any nano- and micro-sized objects can be a controlling agent.
  • the colloidal and other physicochemical characteristics of the controlling agent are close to or similar to said polynucleotide delivery agent. This allows you to increase the effectiveness and information content of such a test. These measurements allow predicting the effect of the antibody on prolonging the circulation time of the agent or its elimination by the phagocytic system.
  • the controlling agent can be various inorganic, organic nano- and microparticles, including magnetic, fluorescent, protein (including those that are cross-linked, polymerized or aggregated protein), polymeric (from polystyrene, dextran, polypeptide, glycolic acid polylactide and etc.) or metallic (gold, silver, semiconductor, etc.) quantum dots, carbon quantum dots, radioactive particles, and other particles.
  • magnetic, fluorescent, protein including those that are cross-linked, polymerized or aggregated protein
  • polymeric from polystyrene, dextran, polypeptide, glycolic acid polylactide and etc.
  • metallic gold, silver, semiconductor, etc.
  • quantum dots carbon quantum dots, radioactive particles, and other particles.
  • the controlling agent can be detected by the product of the signal, incl. at least one of the following: fluorescent, fluorescent, PET, MRI contrast, radiopaque, magnetic, or plasmon resonance.
  • Fig. 1 The dynamics of the circulation of magnetic particles introduced into the bloodstream of the mouse, measured as indicated in Example 3. In addition, an exponential approximation of the dynamics of magnetic particles is shown to determine the half-life of particles from the bloodstream.
  • Fig. 2 Increase in the circulation time of liposomes loaded with magnetite in the case of administration after injection of a solution of monoclonal mouse antibodies against mouse erythrocytes (clone 34-3C) as described in example 4.
  • Fig.Z Deceleration of tumor growth upon administration of a composition containing antibodies against erythrocytes and a lipid-containing agent as described in Example 14.
  • Black triangle, solid line tumor growth in a test group of mice injected with a lipid-containing agent after administration of anti-erythrocyte antibodies;
  • black circle, dashed line tumor growth in the control group of mice, which were injected with a lipid-containing agent without administration of anti-erythrocyte antibodies.
  • Fig. 4 Fluorescent signal of organ homogenates in mice administered with AAV-DJ virus with and without administration of 34-3C antibodies (as described in Example 24).
  • a solution of 22 mg of cholesterol and 42 mg of fosatidylcholine in 6 ml of a mixture of chloroform / methanol (in a ratio of 6: 1) was evaporated from a round bottom flask in a rotary evaporator. Then, 1.5 ml of a 1% solution of magnetite nanoparticles coated with citrate in 125 mM ammonium sulfate was added to the flask. Then, the liposomes are processed in an ultrasonic bath and then passed through an extruder with a membrane installed with a pore size of 100 nm. Then, the liposomes are magnetically separated from the not included magnetite and transferred to physical. solution. The final concentration of liposomes is adjusted to 200 ⁇ g magnetite / 100 ⁇ l suspension.
  • a solution of 22 mg of cholesterol and 42 mg of fosatidylcholine in 6 ml of a mixture of chloroform / methanol (in a ratio of 6: 1) was evaporated from a round bottom flask in a rotary evaporator. Then, 1.5 ml of a 1% solution of magnetite nanoparticles coated with citrate in 125 mM ammonium sulfate was added to the flask. Then, the liposomes are processed in an ultrasonic bath and then passed through an extruder with a membrane installed with a pore size of 100 nm.
  • the liposomes are magnetically separated from the unencumbered magnetite and transferred into a doxorubicin hydrochloride solution at the rate of 33 ⁇ g of doxorubicin hydrochloride per 1 mg of lipid. Then the resulting mixture is incubated at 60 ° C for 15 minutes, after which the liposomes are magnetically separated from the non-included doxorubicin and transferred to physical. solution. The final concentration of liposomes is adjusted to 200 ⁇ g magnetite / 100 ⁇ l suspension.
  • Example 3 Measurement of the circulation time of liposomes loaded with magnetite in the bloodstream of a mouse.
  • the tail of a Balb / c mouse was placed in the coil of the MPQ magnetic nanoparticle detector created by the inventor and described earlier in [Nikitin PI, Vetoshko PM. Magnetic susceptibility meter. RF patent 2177611 (2000), see also Nikitin et al. Nat Nanotechnol, 2014], and fixed. Then, 100 ⁇ l of a suspension of liposomes loaded with magnetite was injected into the retroorbital sinus, and the dynamics of the content of magnetite in the bloodstream of the tail veins and arteries of the mouse was recorded (see Fig. 1). The half-life of particles from the bloodstream was calculated either by approximating the obtained data by an exponential dependence, or as the average time required for a 2-fold decrease in the signal in the middle section of the curve.
  • Example 4 Increasing the circulation time of liposomes loaded with magnetite.
  • Example 5 Increasing the circulation time of liposomes loaded with doxorubicin.
  • a solution of monoclonal mouse antibodies against mouse erythrocytes (clone 34-3C) (or an equal volume of 100 ⁇ l of saline in the control experiment) was injected into Balb / c mice at a dosage of 1.3-3 mg / kg intraperitoneally or into the retroorbital sinus. Then, 10-15 hours later, liposomes loaded with magnetite were injected into the retroorbital sinus, and the dynamics of the concentration of particles in the bloodstream was measured by measuring the fluorescent signal of doxorubicin in selected blood samples every 3 hours. The circulation time of the particles was defined as “the area under curve "(area under curve - AUC). It turned out to be on average 7.1 times higher with the introduction of antibodies than in the control experiments.
  • Example 6 Increasing the circulation time of PEGylated liposomes loaded with doxorubicin.
  • a solution of monoclonal mouse antibodies against mouse erythrocytes (clone 34-3C) (or an equal volume of 100 ⁇ l of saline in the control experiment) was injected into Balb / c mice at a dosage of 1.3-3 mg / kg intraperitoneally or into the retroorbital sinus. Then, 10-15 hours later, PEGylated liposomes loaded with doxorubicin were injected into the retroorbital sinus, and the dynamics of the concentration of particles in the bloodstream was measured by measuring the fluorescent signal of doxorubicin in collected blood samples every 3 hours. Particle circulation time was defined as the area under curve (AUC). It turned out to be on average 42% higher with the introduction of antibodies than in the control experiments.
  • AUC area under curve
  • Example 7 Increasing the circulation time of liposomes loaded with magnetite and doxorubicin.
  • Example 8 Increasing the circulation time of liposomes loaded with magnetite in the bloodstream using a complex of cells and antibodies.
  • a solution of monoclonal mouse antibodies against mouse erythrocytes (clone 34-3C) (or an equal volume of saline in the control experiment) was incubated for 1 hour with erythrocytes isolated from 100-200 ⁇ l of mouse blood (three times centrifuged with phosphate buffered saline). The resulting complexes of erythrocytes and antibodies were injected into the retroorbital sinus in Balb / c mice. Then, 10 hours later, liposomes loaded with magnetite were injected into the retroorbital sinus, and the dynamics of the concentration of particles in the bloodstream was measured as described in example 3. The half-life of particles with the introduction of a complex of antibodies and cells was on average 2.5 times higher than in control experiments.
  • Example 10 The effectiveness of increasing circulation time with repeated administrations of a liposome-based composition loaded with magnetite.
  • Example 11 Increasing the efficiency of delivery of liposomes loaded with magnetite and doxorubicin into a tumor.
  • Mice were injected subcutaneously with 10 L of 6 B16F10 melanoma cells. After the development of tumors, mice with a tumor in the size of 150-200 cubic meters. mm with a neodymium magnet attached to the tumor, liposomes loaded with magnetite and doxorubicin were injected as described in Example 4 (after and without administration of a solution of monoclonal mouse antibodies against mouse erythrocytes). Organs and tumor were extracted 5 hours after particle injection.
  • the content of magnetic particles in the tumor was measured using a magnetic nanoparticle detector created by the author of the invention and described earlier in [Nikitin PI, Vetoshko PM. Magnetic susceptibility meter. RF patent 2177611 (2000)].
  • the content of particles (per gram of tissue) in tumors of mice in the case of administration of anti-erythrocyte antibodies was, on average, 7.3 times higher than the content of particles in tumors of mice in the case of no administration of anti-erythrocyte antibodies.
  • the non-invasive detection of these liposomes in the tumor using the MPQ method makes it possible to diagnose the presence of a tumor.
  • the same experiment was repeated with other tumors.
  • the efficiency of delivery to the tumor when the agent was injected after antibodies increased 3.4 times for the BT-474 human breast tumor xenograft, and 2.5 times for Lewis lung carcinoma.
  • Example 12 Increasing the efficiency of delivery of liposomes loaded with magnetite and doxorubicin into a tumor by preliminary administration of xenogeneic antibodies against erythrocytes.
  • mice were injected subcutaneously with 10 L of 6 B16F10 melanoma cells. After the development of tumors, mice with a tumor measuring 50-200 cubic meters. mm, liposomes loaded with magnetite and doxorubicin were injected 12 hours after administration of a solution of polyclonal rabbit gamma immunoglobulins against mouse erythrocytes at a dosage of 50 mg / kg or without the introduction of such antibodies. Organs and tumor were extracted 5 hours after particle injection. The content of magnetic particles in the tumor was measured using a magnetic nanoparticle detector, as in Example 11. The content of particles (per gram of tissue) in tumors of mice in the case of administration of anti-erythrocyte antibodies was on average 2 times greater than the content of particles in tumors of mice in the case of without the introduction of anti-erythrocyte antibodies.
  • Example 13 Increasing the circulation time of liposomes loaded with magnetite in the bloodstream of a mouse by the introduction of polyclonal xenogeneic antibodies and secondary allogeneic antibodies.
  • a solution of polyclonal rabbit antibodies (gamma-immunoglobulins) against mouse erythrocytes (or an equal volume of 100 ⁇ l of saline in the control experiment) was intravenously injected into Balb / c mice at a dosage of 10 mg / kg. After 1 hour, the mice were intravenously injected with a solution of polyclonal mouse antibodies against rabbit gamma-immunoglobulins (or an equal volume of 100 ⁇ l of physiological saline in the control experiment) at a dosage of 1.3-3 mg / kg.
  • liposomes loaded with magnetite were injected into the retroorbital sinus, and the dynamics of the concentration of particles in the bloodstream was measured as described in example 3.
  • the half-life of particles with the introduction of rabbit and mouse antibodies was on average 2.3 times longer than in control experiments (without the introduction of antibodies).
  • Example 14 Slowdown of tumor growth upon administration of a composition containing antibodies against erythrocytes and a lipid-containing agent.
  • mice were injected subcutaneously with 10 L of 6 B16F10 melanoma cells. After the development of tumors, mice with a tumor of about 50-200 cubic meters. mm was first injected with a solution of monoclonal mouse antibodies against mouse erythrocytes (as described in Example 3) and nothing was administered to the mice in the control group. Then, 12 hours later, mice of both groups were injected with liposomes loaded with magnetite and doxorubicin (with a neodymium magnet attached to the tumor). Tumor growth in both cases is shown in Fig. 3. As can be seen from Fig. 3, the tumor size 10 days after the injection of liposomes after the injection with the antibody was 3.5 times smaller than after the injection of liposomes.
  • Example 15 Extension of the lifetime of animals with melanoma upon administration of a composition containing antibodies against erythrocytes and a lipid-containing agent. Mice were injected subcutaneously with 10 L of 6 B16F10 melanoma cells. After the development of tumors, mice with a tumor of about 50-200 cubic meters. mm was first introduced a solution of monoclonal mouse antibodies against mouse erythrocytes (as described in Example 3) or physical. solution in the control group, and then 12 hours later liposomes loaded with magnetite and doxorubicin (with a neodymium magnet attached to the tumor).
  • the average survival time of animals in the group to which the agent with doxorubicin was administered after administration of monoclonal mouse antibodies against mouse erythrocytes turned out to be longer than the average life time in the group of animals to which only the agent was administered by 30%.
  • Example 16 Inhibition of tumor growth with the introduction of antibodies against erythrocytes and PEGylated liposomal doxorubicin.
  • mice were injected subcutaneously with 10 L of 6 B16F10 melanoma cells. After the development of tumors, mice with a tumor of about 50-200 cubic meters. mm was first injected with a solution of monoclonal mouse antibodies against mouse erythrocytes (as described in Example 3) and nothing was administered to the mice in the control group. Then, 12 hours later, mice of both groups were injected with the preparation of PEGylated liposomal doxorubicin Kelix. The tumor size 10 days after the injection of liposomes after the injection with the antibody was 1.9 times smaller than after the injection of liposomes alone.
  • Example 17 Extension of the survival time of animals with melanoma with the introduction of antibodies against erythrocytes and PEGylated liposomal doxorubicin.
  • mice were injected subcutaneously with 10 L of 6 B16F10 melanoma cells. After the development of tumors, mice with a tumor of about 50-200 cubic meters. mm was first introduced a solution of monoclonal mouse antibodies against mouse erythrocytes (as described in Example 3) or physical. solution in the control group, and then, 12 hours later, the preparation of PEGylated liposomal doxorubicin Kelix was administered. The average survival time of animals in the group to which Kelix was injected after the administration of monoclonal mouse antibodies against mouse erythrocytes turned out to be longer than the average lifetime in the group of animals to which only the agent was administered, by 23%.
  • Example 18 Increasing the circulation time of magnetic nanoparticles by the introduction of antibodies against CD47.
  • a solution of monoclonal mouse antibodies against mouse / rat / human CD47 (clone MIAP410) (or equal volume - 100 ⁇ l - saline in the control experiment) was injected into Balb / c mice at a dosage of 1.3-3 mg / kg intraperitoneally or into the retroorbital sinus. Then, 10-15 hours later, magnetic nanoparticles Chemicell fluidMAG-ARA-lOOnm were injected into the retroorbital sinus, and the dynamics of the concentration of particles in the bloodstream was measured as described in example 3. The half-life of particles with the introduction of antibodies was on average 3.2 times higher than in the control experiments.
  • Example 19 Increasing the circulation time of magnetic nanoparticles by introducing a mixture of antibodies 34-3C and MIAP410.
  • Example 20 Increasing the circulation time of magnetic nanoparticles by introducing a mixture of antibodies 34-3C and Fab-fragments of antibodies against CD47.
  • Example 21 Increasing the circulation time of magnetic liposomes by the introduction of antibodies against CD47.
  • a solution of monoclonal mouse antibodies against mouse / rat / human CD47 (clone MIAP410) (or equal volume - 100 ⁇ l - saline in the control experiment) was injected into Balb / c mice at a dosage of 1.25 mg / kg intraperitoneally or into the retroorbital sinus. Then, 10-15 hours later, liposomes loaded with magnetite were injected into the retroorbital sinus, and the dynamics of the concentration of particles in the bloodstream was measured as described in example 3. The half-life of particles with the introduction of antibodies was on average 2.5 times higher than in control experiments.
  • Example 22 Increasing the circulation time of liposomes loaded with magnetite in the bloodstream using a complex of cells and antibodies against CD47.
  • Example 23 Increasing the circulation time of liposomes loaded with magnetite in the bloodstream using a complex of cells and a mixture of antibodies 34-3C and MIAP410.
  • liposomes loaded with magnetite were injected into the retroorbital sinus, and the dynamics of the concentration of particles in the bloodstream was measured as described in example 3.
  • the half-life of particles with the introduction of a complex of antibodies and cells was on average 3.2 times higher than in control experiments.
  • Example 24 Increasing the efficiency of delivery of a gene (polynucleotide) encoding a protein using a virus.
  • the AAV-DJ virus with an inserted polynucleotide expressing the fluorescent protein GFP is injected into Balb / c mice without the administration of 34-3C antibodies or 12 hours after the administration of 34-3C (as described in Example 4). After 3 weeks, the organs of the animal are extracted, homogenized, centrifuged, and the expression level of the reporter protein is measured using a fluorometer.
  • Figure 4 shows significantly greater protein expression in mice treated with 34-3C antibody as compared to controls.
  • Example 25 Synthesis of a polynucleotide delivery agent using a cationic lipid agent DOTAP (lipid containing agent).
  • DOTAP lipid containing agent
  • a solution of DOTAP and cholesterol in chloroform in a ratio of 3 to 1 by weight is evaporated on a rotary vacuum evaporator at 45 degrees (until a thin lipid film is formed on the walls of the flask). Then, a 5% glucose solution is added, treated with ultrasound, and the resulting suspension is pushed through 100-nm polycarbonate membranes. Then, mix the liposome suspension with plasmid DNA (encoding Nanoluc luciferase) in a ratio of 4: 1 by weight (4 mg of liposomes are added to 1 mg of DNA). Then incubated for 20 minutes.
  • Example 26 Increasing the efficiency of delivery to the lungs of a gene (polynucleotide) encoding a protein using a cationic lipid-based agent DOTAP (lipid-containing agent).
  • DOTAP lipid-containing agent
  • the obtained lipoplexes from Example 25 (in an amount of 100 ⁇ g by plasmid DNA) were injected into Balb / c mice without the administration of 34-3C antibodies or 12 hours after the administration of 34-3C (as described in Example 4). After 24 hours, the lungs are extracted, homogenized, centrifuged and the substrate coelenterazine-h is added to the aliquot and the level of luciferase expression is measured using a luminometer. The expression of luciferase (by the level of luminescence) in the case of mice injected with the 34-3C antibody is 76% higher than in the control.
  • Example 27 Synthesis of magnetic nanoagents for delivery of heterologous polynucleotide.
  • Magnetite particles are synthesized as described in Nikitin et al. Nat Nanotechnol. 2014 coated with sodium citrate (as in Example 1). Then, to 1 mg of this particle add 15 mg of branched polyethyleneimine (average molecular weight 25 kDa), incubate for 30 minutes at room temperature, sonicating every 5 minutes. The particles are washed three times with water, separating the particles on a magnet. Finally, resuspend the particles in phosphate buffered saline using an ultrasonic bath.
  • Example 28 Increasing the efficiency of delivery to the lungs of a gene (polynucleotide) using magnetic agents and the TER-119 antibody.
  • the obtained magnetic nanoagents from Example 27 (in an amount of 100 ⁇ g for plasmid DNA) were injected into Balb / c mice without the administration of TER-119 antibodies or 12 hours after the administration of TER-119 (as described in Example 4). After 24 hours, the lungs are extracted, homogenized, centrifuged and the substrate coelenterazine-h is added to the aliquot and the level of luciferase expression is measured using a luminometer. The expression of luciferase (by the level of luminescence) in the case of mice with the injected antibody 34-3C is 1.5 times higher than in the control (without the introduction of 34-3C).
  • Example 29 Increasing the efficiency of delivery to the lungs of a gene (polynucleotide) using magnetic agents and antibody 34-3C.
  • the obtained magnetic nanoagents from Example 27 (in an amount of 100 ⁇ g for plasmid DNA) were injected into Balb / c mice without the administration of TER-119 antibodies or 12 hours after the administration of TER-119 (as described in Example 4). After 24 hours, the lungs are extracted, homogenized, centrifuged and the substrate coelenterazine-h is added to the aliquot and the level of luciferase expression is measured using a luminometer. The expression of luciferase (by the level of luminescence) in the case of mice with the injected antibody 34-3C is 1.9 times higher than in the control (without the introduction of 34-3C).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Virology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

L'invention se rapporte au domaine de la bio-médecine et de la nano-médecine, et concerne notamment des compositions et des procédés pour traiter et diagnostiquer des maladies à l'aide d'agents médicamenteux contenant des lipides, ainsi que des compositions et des procédés d'amélioration de la circulation du flux sanguin, d'administration vers des cibles, et de l'efficacité thérapeutique et/ou diagnostique des agents médicamenteux contenant des lipides. Cette invention concerne essentiellement une composition que l'on utilise dans un procédé de thérapie ou de diagnostic de maladies ou d'états de l'organisme, laquelle comprend au moins i) un anticorps avec une forme moléculaire libre contre les cellules sanguines du patient, et ii) un agent médicamenteux contenant un lipide. Le résultat technique de la présente invention consiste en une amélioration de la circulation dans le flux sanguin, de l'efficacité de traitement et de diagnostic de maladies à l'aide d'agents médicamenteux contenant des lipides.
PCT/RU2021/050193 2020-07-03 2021-07-01 Composition pour thérapie et diagnostic à base d'anticorps WO2022005339A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020122138 2020-07-03
RU2020122138 2020-07-03

Publications (1)

Publication Number Publication Date
WO2022005339A1 true WO2022005339A1 (fr) 2022-01-06

Family

ID=79317813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2021/050193 WO2022005339A1 (fr) 2020-07-03 2021-07-01 Composition pour thérapie et diagnostic à base d'anticorps

Country Status (1)

Country Link
WO (1) WO2022005339A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Rh 0 (D) Immune Globulin Intravenous (Human) 1500 IU (300 mcg)", RHOPHYLAC, 1 January 2004 (2004-01-01), XP055897192, Retrieved from the Internet <URL:https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB11597.pdf?1496764853> *
PATRA JAYANTA KUMAR, DAS GITISHREE, FRACETO LEONARDO FERNANDES, CAMPOS ESTEFANIA VANGELIE RAMOS, RODRIGUEZ-TORRES MARIA DEL PILAR,: "Nano based drug delivery systems: recent developments and future prospects", JOURNAL OF NANOBIOTECHNOLOGY, vol. 16, no. 1, 1 December 2018 (2018-12-01), pages 71, XP055897188, DOI: 10.1186/s12951-018-0392-8 *

Similar Documents

Publication Publication Date Title
Chen et al. Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier
Dufès et al. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells
KR102541164B1 (ko) 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도
Afergan et al. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes
Yang Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis
Torchilin Passive and active drug targeting: drug delivery to tumors as an example
Fatima et al. Folic acid conjugated poly (amidoamine) dendrimer as a smart nanocarriers for tracing, imaging, and treating cancers over-expressing folate receptors
Kim et al. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy
Wiwatchaitawee et al. Enhancement of therapies for glioblastoma (GBM) using nanoparticle-based delivery systems
US20130243867A1 (en) Micelle compositions and methods for their use
Hoang et al. Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts
US20070160658A1 (en) Delivery system for diagnostic and therapeutic agents
Zhuo et al. Tumor imaging and interferon-γ–inducible protein-10 gene transfer using a highly efficient transferrin-conjugated liposome system in mice
JP2000516630A (ja) 全身への送達を増加させる新規のリポソーム複合体
KR20140102294A (ko) 뇌 종양에 대한 치료제의 전달을 위한 박테리아 유래된, 무손상 미니세포
CN112076158B (zh) 一种治疗慢性肾炎的脂质体-纳米粒复合体
Ali et al. Significance and applications of nanoparticles in siRNA delivery for cancer therapy
Zhang et al. Phosphatidylserine-targeted liposome for enhanced glioma-selective imaging
US9439978B2 (en) Multilayered magnetic micelle compositions and methods for their use
WO2022005339A1 (fr) Composition pour thérapie et diagnostic à base d&#39;anticorps
WO2022005342A1 (fr) Composition et procédé de production d&#39;acides nucléiques
WO2022005341A1 (fr) Composition et procédé pour réduire les effets secondaires d&#39;un agent thérapeutique
WO2022005340A1 (fr) Composition comprenant un agent thérapeutique liposomal
WO2016076760A2 (fr) Substance et procédé d&#39;utilisation de cette substance pour moduler l&#39;activité d&#39;un agent dans le corps
Manicum et al. Nano-immunotherapeutic strategies for targeted RNA delivery: Emphasizing the role of monocyte/macrophages as nanovehicles to treat glioblastoma multiforme

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21832935

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21832935

Country of ref document: EP

Kind code of ref document: A1